MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 6 | 4.0 |
Embryo Transfer/*standards | 6 | 4.0 |
Female | 1148 | 1.0 |
Humans | 2816 | 1.0 |
Meta-Analysis | 6 | 3.0 |
Pregnancy | 43 | 0.0 |
Pregnancy Outcome | 7 | 2.0 |
Pregnancy Rate | 6 | 4.0 |
Pregnancy, Multiple | 6 | 4.0 |
Randomized Controlled Trials | 20 | 4.0 |
Review Literature | 6 | 4.0 |
Acute Disease | 4 | 0.0 |
Adult | 612 | 1.0 |
Bone Marrow Transplantation/*statistics & numerical data | 4 | 4.0 |
Comparative Study | 284 | 1.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 4 | 4.0 |
Fetal Blood/transplantation | 4 | 4.0 |
Leukemia/*therapy | 4 | 3.0 |
Patient Selection | 7 | 3.0 |
Animals | 754 | 1.0 |
*Computational Biology | 2 | 3.0 |
Oligonucleotide Array Sequence Analysis | 14 | 1.0 |
Adenocarcinoma/genetics | 5 | 6.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
Carcinoma, Non-Small-Cell Lung/genetics | 3 | 15.0 |
DNA, Viral/analysis | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Genes, erbB-1/*genetics | 7 | 87.0 |
Genes, ras/*genetics | 7 | 7.0 |
Japan | 3 | 0.0 |
Lung Neoplasms/*genetics/pathology | 3 | 3.0 |
Male | 686 | 0.0 |
*Mutation | 39 | 0.0 |
Mutation, Missense | 5 | 0.0 |
Neoplasm Staging | 158 | 6.0 |
Papillomavirus, Human/genetics | 3 | 7.0 |
Protein-Tyrosine Kinase/*genetics | 3 | 1.0 |
Research Support, Non-U.S. Gov't | 1529 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 728 | 1.0 |
Sequence Analysis, DNA | 12 | 0.0 |
Taiwan | 2 | 1.0 |
United States | 2 | 0.0 |
Albumins/metabolism | 4 | 2.0 |
Albuminuria/*prevention & control | 4 | 4.0 |
Antihypertensive Agents/*therapeutic use | 4 | 1.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 4 | 4.0 |
Hypertension/complications/*drug therapy | 4 | 3.0 |
Indoles/*therapeutic use | 4 | 3.0 |
Renin-Angiotensin System/*drug effects | 4 | 3.0 |
*Education, Medical, Graduate | 2 | 6.0 |
*Educational Status | 2 | 6.0 |
*Students, Medical | 2 | 5.0 |
Surgery/*education | 2 | 5.0 |
Aged | 576 | 1.0 |
*Aging | 3 | 1.0 |
Cohort Studies | 28 | 1.0 |
Confounding Factors (Epidemiology) | 2 | 3.0 |
United States/epidemiology | 3 | 0.0 |
Cell Line | 266 | 1.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Hamsters | 39 | 0.0 |
Nucleic Acid Hybridization/*methods | 2 | 4.0 |
Protein Biosynthesis | 7 | 0.0 |
Proto-Oncogene Proteins/genetics | 17 | 3.0 |
Rabbits | 11 | 0.0 |
Transcription Factors/genetics | 4 | 0.0 |
Transcription, Genetic | 42 | 0.0 |
Child | 77 | 0.0 |
Base Sequence | 136 | 0.0 |
Brain/metabolism | 5 | 0.0 |
*Down-Regulation | 9 | 2.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Molecular Sequence Data | 187 | 0.0 |
Mutation/genetics | 18 | 1.0 |
*Oligonucleotide Array Sequence Analysis | 6 | 3.0 |
Organ Specificity | 6 | 0.0 |
Substrate Specificity | 16 | 0.0 |
Magnetic Resonance Imaging | 9 | 0.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Swine | 8 | 0.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Carrier Proteins/genetics/*metabolism | 5 | 1.0 |
Endocytosis/physiology | 5 | 6.0 |
Macromolecular Substances | 15 | 0.0 |
Mice | 441 | 1.0 |
Protein Binding | 98 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 10 | 2.0 |
RNA, Small Interfering/genetics/metabolism | 2 | 4.0 |
Receptor, Epidermal Growth Factor/genetics/*metabolism | 92 | 57.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Ubiquitin/metabolism | 8 | 3.0 |
Epidermal Growth Factor/*pharmacokinetics | 2 | 33.0 |
Receptor, Epidermal Growth Factor/metabolism | 166 | 30.0 |
Cells, Cultured | 125 | 0.0 |
Enzyme Activation | 106 | 3.0 |
Epidermal Growth Factor/pharmacology | 97 | 11.0 |
Microscopy, Fluorescence | 38 | 2.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 38 | 10.0 |
Mitogen-Activated Protein Kinase 3 | 45 | 7.0 |
Mitogen-Activated Protein Kinases/*metabolism | 44 | 8.0 |
Osmolar Concentration | 2 | 0.0 |
Phosphorylation | 361 | 4.0 |
Trans-Activation (Genetics)/*drug effects | 3 | 3.0 |
p38 Mitogen-Activated Protein Kinases | 14 | 2.0 |
*Cell Movement | 4 | 3.0 |
Collagen | 4 | 2.0 |
Drug Combinations | 11 | 2.0 |
Enzyme Inhibitors/pharmacology | 86 | 3.0 |
Estrenes/pharmacology | 4 | 10.0 |
Herpesvirus 4, Human/*physiology | 2 | 3.0 |
Integrins/physiology | 2 | 2.0 |
Laminin | 5 | 5.0 |
*Neoplasm Invasiveness | 10 | 13.0 |
Protein-Tyrosine Kinase/metabolism | 32 | 3.0 |
Proteoglycans | 4 | 4.0 |
Pyrrolidinones/pharmacology | 4 | 7.0 |
Quinazolines/pharmacology | 27 | 35.0 |
Signal Transduction | 213 | 3.0 |
Tumor Cells, Cultured | 580 | 3.0 |
*Drosophila Proteins | 10 | 0.0 |
*Gene Rearrangement | 5 | 2.0 |
Proto-Oncogene Proteins/*genetics | 20 | 2.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 4 | 1.0 |
Brain Neoplasms/*genetics | 26 | 18.0 |
Chromosome Deletion | 12 | 1.0 |
DNA Mutational Analysis | 18 | 0.0 |
DNA, Neoplasm/genetics | 29 | 3.0 |
Gene Amplification/genetics | 6 | 10.0 |
Glioblastoma/genetics | 5 | 17.0 |
Immunohistochemistry/methods | 28 | 4.0 |
Loss of Heterozygosity/genetics | 6 | 4.0 |
Middle Aged | 708 | 1.0 |
Nucleic Acid Hybridization | 31 | 2.0 |
Antigens, CD95/metabolism | 2 | 1.0 |
Caspases/metabolism | 8 | 1.0 |
Mitochondria/metabolism | 4 | 1.0 |
NF-kappa B/metabolism | 4 | 0.0 |
Biological Markers/analysis | 11 | 1.0 |
Epidermal Growth Factor/analysis | 10 | 17.0 |
Keratin/*analysis | 2 | 6.0 |
Transforming Growth Factors/analysis | 3 | 42.0 |
Amino Acid Sequence | 115 | 0.0 |
Binding Sites | 61 | 0.0 |
Epidermal Growth Factor/immunology/*metabolism | 2 | 28.0 |
Models, Molecular | 15 | 0.0 |
Mutagenesis, Site-Directed | 25 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/genetics/*metabolism | 7 | 43.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 180 | 1.0 |
Two-Hybrid System Techniques | 10 | 0.0 |
Fluorescent Antibody Technique/*methods | 2 | 33.0 |
Immunochemistry | 3 | 1.0 |
Models, Biological | 57 | 1.0 |
Receptor, Epidermal Growth Factor/*analysis/genetics/immunology | 3 | 75.0 |
Reproducibility of Results | 10 | 0.0 |
Sensitivity and Specificity | 43 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 24 | 4.0 |
*Adaptor Proteins, Signal Transducing | 53 | 4.0 |
*Adaptor Proteins, Vesicular Transport | 21 | 8.0 |
Cyclin D1/metabolism | 9 | 6.0 |
Enzyme Activation/radiation effects | 5 | 20.0 |
Hela Cells | 48 | 0.0 |
Ligands | 142 | 5.0 |
Phosphorylation/radiation effects | 5 | 16.0 |
*Protein-Serine-Threonine Kinases | 38 | 4.0 |
Proteins/metabolism | 31 | 3.0 |
Proto-Oncogene Proteins/metabolism | 55 | 4.0 |
Receptor, Epidermal Growth Factor/*metabolism | 397 | 50.0 |
Signal Transduction/*radiation effects | 4 | 21.0 |
Ultraviolet Rays | 10 | 1.0 |
ras Proteins/*metabolism | 6 | 3.0 |
Blotting, Northern | 70 | 1.0 |
Blotting, Western | 178 | 2.0 |
Coculture Techniques | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 45 | 1.0 |
Epidermal Growth Factor/*metabolism | 87 | 22.0 |
Epithelium/pathology | 10 | 7.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Metalloendopeptidases/*metabolism | 8 | 8.0 |
RNA, Messenger/metabolism | 50 | 1.0 |
Receptor, Epidermal Growth Factor/*genetics/*metabolism | 8 | 53.0 |
Time Factors | 154 | 1.0 |
*Trans-Activation (Genetics) | 16 | 2.0 |
Tyrosine/metabolism | 75 | 6.0 |
Aged, 80 and over | 251 | 2.0 |
Biopsy, Needle | 19 | 4.0 |
Culture Techniques | 8 | 1.0 |
Immunohistochemistry | 515 | 4.0 |
Lymph Nodes/*pathology | 5 | 5.0 |
Lymphatic Metastasis | 92 | 9.0 |
Probability | 13 | 2.0 |
Prognosis | 369 | 5.0 |
Protein p53/*analysis | 21 | 11.0 |
Receptor, Epidermal Growth Factor/*analysis | 252 | 69.0 |
Receptor, erbB-2/*analysis | 40 | 48.0 |
Tumor Markers, Biological/*analysis | 100 | 10.0 |
Brain Neoplasms/*therapy | 2 | 28.0 |
Disease Models, Animal | 23 | 1.0 |
Liposomes/metabolism | 3 | 5.0 |
Mice, SCID | 16 | 2.0 |
Neoplasms, Experimental | 2 | 5.0 |
Receptor, Epidermal Growth Factor/*genetics | 156 | 67.0 |
Cyclin D1/genetics | 8 | 12.0 |
DNA/genetics | 7 | 0.0 |
English Abstract | 147 | 1.0 |
Esophageal Neoplasms/*genetics | 5 | 6.0 |
Genes, DCC | 2 | 10.0 |
Genes, Tumor Suppressor | 16 | 1.0 |
Genes, p53 | 32 | 6.0 |
Genes, ras | 10 | 4.0 |
Ploidies | 32 | 12.0 |
Antigens, CD44/metabolism | 4 | 4.0 |
Cell Division/drug effects | 161 | 4.0 |
Gene Expression Regulation/drug effects | 5 | 0.0 |
Glioblastoma/*metabolism/pathology | 3 | 25.0 |
Mitogen-Activated Protein Kinases/metabolism | 71 | 6.0 |
Neoplasm Invasiveness/pathology | 5 | 8.0 |
Phosphorylation/drug effects | 64 | 7.0 |
Precipitin Tests | 81 | 2.0 |
Receptor, Epidermal Growth Factor/*physiology | 68 | 46.0 |
Receptor, erbB-2/metabolism | 48 | 29.0 |
Urinary Plasminogen Activator/metabolism | 3 | 6.0 |
Bronchi/cytology/metabolism | 2 | 13.0 |
*Intercellular Signaling Peptides and Proteins | 30 | 5.0 |
Respiratory Mucosa/*metabolism | 3 | 21.0 |
Smoking/*metabolism | 2 | 4.0 |
Cell Differentiation/*physiology | 3 | 1.0 |
Cells, Cultured/cytology | 2 | 14.0 |
Green Fluorescent Proteins | 14 | 1.0 |
Homozygote | 10 | 0.0 |
Immunoenzyme Techniques | 127 | 3.0 |
Infusion Pumps, Implantable | 3 | 17.0 |
Luminescent Proteins/metabolism | 7 | 1.0 |
Protein p16/*metabolism | 2 | 6.0 |
Protein p53/metabolism | 25 | 4.0 |
Retroviridae/genetics | 7 | 1.0 |
Analysis of Variance | 32 | 1.0 |
Breast Neoplasms/mortality/*pathology | 2 | 33.0 |
Confidence Intervals | 4 | 1.0 |
Multivariate Analysis | 64 | 4.0 |
Proportional Hazards Models | 32 | 4.0 |
Sampling Studies | 3 | 1.0 |
Survival Analysis | 122 | 5.0 |
DNA-Binding Proteins/*metabolism | 12 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Proteins/physiology | 2 | 1.0 |
*Repressor Proteins | 6 | 0.0 |
*Signal Transduction | 77 | 3.0 |
Trans-Activators/*metabolism | 12 | 1.0 |
*Transcription Factors | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 89 | 1.0 |
Transfection | 202 | 1.0 |
Tyrphostins/pharmacology | 43 | 28.0 |
Up-Regulation | 57 | 2.0 |
Antibodies, Monoclonal/*immunology | 10 | 1.0 |
Antibody Affinity | 5 | 2.0 |
Heparin/pharmacology | 2 | 0.0 |
Iodine Radioisotopes | 11 | 3.0 |
Mice, Inbred BALB C | 63 | 2.0 |
Radioimmunodetection | 5 | 29.0 |
Carcinoma, Squamous Cell/metabolism/*pathology | 2 | 7.0 |
Cell Movement/*drug effects | 4 | 4.0 |
Down-Regulation | 64 | 3.0 |
Endothelial Growth Factors/*metabolism | 6 | 1.0 |
Head and Neck Neoplasms/metabolism/*pathology | 2 | 28.0 |
Intercellular Signaling Peptides and Proteins/*metabolism | 4 | 4.0 |
Lymphokines/*metabolism | 6 | 1.0 |
Oligonucleotides, Antisense/*pharmacology | 10 | 10.0 |
Tumor Cells, Cultured/*drug effects/metabolism | 2 | 7.0 |
Vascular Endothelial Growth Factor A | 38 | 1.0 |
Vascular Endothelial Growth Factors | 38 | 1.0 |
Adenocarcinoma/*metabolism | 5 | 5.0 |
Lung Neoplasms/*metabolism | 4 | 5.0 |
Prospective Studies | 43 | 1.0 |
Tissue Plasminogen Activator/*metabolism | 2 | 10.0 |
DNA-Binding Proteins/antagonists & inhibitors/metabolism | 2 | 9.0 |
Enzyme Inhibitors/*pharmacology | 50 | 7.0 |
Guanosine Triphosphate/metabolism | 6 | 1.0 |
Kinetics | 100 | 1.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/metabolism | 2 | 6.0 |
Tyrphostins/*pharmacology | 6 | 24.0 |
Antineoplastic Agents/adverse effects/*therapeutic use | 8 | 24.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy | 15 | 57.0 |
Disease Progression | 68 | 2.0 |
Drug Resistance, Neoplasm | 19 | 3.0 |
Lung Neoplasms/*drug therapy | 20 | 40.0 |
Palliative Care | 3 | 7.0 |
Treatment Failure | 5 | 1.0 |
Antibodies, Monoclonal/therapeutic use | 28 | 14.0 |
Antineoplastic Agents/*therapeutic use | 65 | 16.0 |
Clinical Trials | 65 | 7.0 |
Colorectal Neoplasms/*drug therapy/pathology | 4 | 33.0 |
Combined Modality Therapy | 43 | 3.0 |
Enzyme Inhibitors/therapeutic use | 12 | 16.0 |
Immunoconjugates/therapeutic use | 2 | 50.0 |
Neoplasm Metastasis | 54 | 5.0 |
Oligodeoxyribonucleotides, Antisense/therapeutic use | 3 | 50.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 39 | 18.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/*physiology | 5 | 100.0 |
Antibodies, Monoclonal | 56 | 2.0 |
*Cell Transformation, Neoplastic | 14 | 3.0 |
Growth Substances/physiology | 5 | 4.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*physiology | 10 | 62.0 |
Estradiol/pharmacology | 3 | 1.0 |
Estrogen Receptor Modulators/pharmacology | 2 | 9.0 |
Estrogen Receptor alpha | 3 | 1.0 |
Estrogen Receptor beta | 2 | 2.0 |
Mice, Nude | 153 | 8.0 |
Neoplasm Transplantation | 82 | 6.0 |
Proteins | 2 | 3.0 |
RNA, Messenger/genetics/metabolism | 21 | 0.0 |
Receptor, Epidermal Growth Factor/biosynthesis/genetics | 13 | 56.0 |
Receptor, erbB-2/biosynthesis/genetics | 2 | 10.0 |
Tamoxifen/pharmacology | 4 | 4.0 |
Transcription, Genetic/drug effects | 6 | 0.0 |
Quinazolines/administration & dosage | 4 | 80.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors | 94 | 77.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 17 | 3.0 |
Cell Division | 182 | 4.0 |
Cisplatin/administration & dosage | 7 | 3.0 |
Fluorouracil/administration & dosage | 9 | 7.0 |
Leucovorin/administration & dosage | 2 | 6.0 |
Neoadjuvant Therapy | 2 | 5.0 |
Receptor, Epidermal Growth Factor/immunology/metabolism | 4 | 80.0 |
Survival Rate | 98 | 4.0 |
Diagnosis, Differential | 18 | 0.0 |
*Tumor Markers, Biological | 7 | 3.0 |
Algorithms | 3 | 0.0 |
Cadherins/analysis | 2 | 6.0 |
Carcinoma, Squamous Cell/*radiotherapy | 5 | 55.0 |
Ki-67 Antigen/analysis | 30 | 10.0 |
Protein p53/analysis | 33 | 11.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 12 | 6.0 |
Receptor, Epidermal Growth Factor/analysis | 93 | 49.0 |
Tumor Markers, Biological/analysis | 33 | 4.0 |
Neoplasms/pathology/*therapy | 2 | 14.0 |
Receptor, Epidermal Growth Factor/analysis/*antagonists & inhibitors | 4 | 80.0 |
Risk Factors | 23 | 0.0 |
Sex Factors | 11 | 0.0 |
Lung Neoplasms/*drug therapy/pathology | 10 | 30.0 |
Neoplasm Recurrence, Local | 27 | 6.0 |
Quinazolines/adverse effects/*therapeutic use | 4 | 80.0 |
Receptor, Epidermal Growth Factor/*drug effects | 11 | 55.0 |
Antineoplastic Agents/pharmacology | 17 | 3.0 |
Disease-Free Survival | 39 | 4.0 |
Odds Ratio | 3 | 0.0 |
Protein Structure, Tertiary | 54 | 1.0 |
Quinazolines/*pharmacology | 56 | 60.0 |
Receptor, Epidermal Growth Factor/*blood | 12 | 92.0 |
Receptor, erbB-2/*blood | 3 | 42.0 |
Treatment Outcome | 67 | 1.0 |
Antineoplastic Agents/*toxicity | 6 | 9.0 |
Apoptosis/*drug effects/physiology | 3 | 2.0 |
Cell Line, Tumor | 139 | 4.0 |
Drug Synergism | 29 | 2.0 |
Mitochondria/drug effects/physiology | 2 | 7.0 |
*Prostatic Neoplasms | 3 | 21.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors | 24 | 63.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 5 | 9.0 |
Breast Neoplasms/*pathology | 19 | 9.0 |
Cell Adhesion | 17 | 1.0 |
*Drug Resistance, Neoplasm | 14 | 8.0 |
Neoplasm Invasiveness | 85 | 7.0 |
Phenotype | 56 | 0.0 |
Tamoxifen/*pharmacology | 8 | 12.0 |
Apoptosis | 49 | 2.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 6 | 11.0 |
*Genes, p53 | 23 | 4.0 |
Keratin/metabolism | 10 | 7.0 |
Mitotic Index | 14 | 8.0 |
Neoplasm Proteins/metabolism | 16 | 4.0 |
Polymerase Chain Reaction/methods | 19 | 1.0 |
Polymorphism, Single-Stranded Conformational | 19 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 14 | 3.0 |
Vimentin/metabolism | 5 | 4.0 |
Rats | 104 | 0.0 |
Rats, Inbred F344 | 7 | 1.0 |
Tissue Distribution | 26 | 0.0 |
Adenoviridae/genetics | 7 | 1.0 |
COS Cells | 29 | 1.0 |
Gene Transfer Techniques | 7 | 1.0 |
Genetic Vectors/genetics | 7 | 2.0 |
Polymerase Chain Reaction | 73 | 0.0 |
Transduction, Genetic | 9 | 2.0 |
Transplantation, Heterologous | 81 | 8.0 |
Cancer Vaccines/therapeutic use | 2 | 16.0 |
Immunity, Cellular | 4 | 0.0 |
Immunotherapy/*methods | 3 | 2.0 |
Calcium/*metabolism | 4 | 0.0 |
Oncogene Proteins v-erbB/metabolism | 4 | 44.0 |
Polymorphism, Genetic | 10 | 0.0 |
Receptors, Cell Surface/metabolism | 5 | 1.0 |
ras Proteins/metabolism | 12 | 7.0 |
Genes, erbB-1/physiology | 4 | 66.0 |
Receptor, Epidermal Growth Factor/genetics/*physiology | 16 | 48.0 |
Signal Transduction/genetics/physiology | 5 | 10.0 |
Retrospective Studies | 75 | 2.0 |
Follow-Up Studies | 67 | 1.0 |
Neoplasms/*drug therapy/metabolism | 5 | 20.0 |
*Organic Chemicals | 4 | 15.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 18 | 3.0 |
Neoplasm Proteins/*analysis | 34 | 10.0 |
Pedigree | 2 | 0.0 |
Preoperative Care | 2 | 1.0 |
Clathrin/metabolism | 5 | 10.0 |
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors/*metabolism | 2 | 15.0 |
Endocytosis/*physiology | 13 | 12.0 |
Epidermal Growth Factor/metabolism | 74 | 19.0 |
Isoquinolines/pharmacology | 3 | 2.0 |
*Sulfonamides | 3 | 5.0 |
Bacterial Proteins | 2 | 6.0 |
Endosomes/metabolism | 10 | 8.0 |
Proteins/*metabolism | 13 | 1.0 |
Recombinant Fusion Proteins/metabolism | 16 | 1.0 |
Androgens/physiology | 3 | 7.0 |
Angiogenesis Inhibitors/*pharmacology | 2 | 2.0 |
Antibodies, Monoclonal/*pharmacology | 17 | 8.0 |
Apoptosis/drug effects | 31 | 4.0 |
Dose-Response Relationship, Drug | 117 | 1.0 |
Neoplasm Metastasis/prevention & control | 2 | 11.0 |
Neovascularization, Pathologic/*prevention & control | 3 | 5.0 |
Paclitaxel/pharmacology | 6 | 6.0 |
Receptor, Epidermal Growth Factor/*immunology/metabolism | 5 | 62.0 |
Xenograft Model Antitumor Assays | 33 | 15.0 |
Antibodies, Monoclonal/*pharmacology/therapeutic use | 7 | 38.0 |
Antigens, CD31/analysis | 4 | 4.0 |
Apoptosis/genetics | 4 | 1.0 |
Drug Therapy, Combination | 6 | 0.0 |
HT29 Cells | 5 | 2.0 |
Receptor, Epidermal Growth Factor/*immunology | 31 | 55.0 |
Biological Markers/blood | 3 | 0.0 |
*Neoadjuvant Therapy | 2 | 20.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 10 | 3.0 |
Endothelial Growth Factors/*biosynthesis | 2 | 1.0 |
Immunoblotting | 58 | 2.0 |
Luciferases/metabolism | 8 | 1.0 |
Lymphokines/*biosynthesis | 2 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 6 | 4.0 |
NF-kappa B/*metabolism | 6 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 14 | 2.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/*metabolism | 7 | 77.0 |
Transcription Factor AP-1/*metabolism | 4 | 2.0 |
Antineoplastic Agents/*pharmacology | 87 | 8.0 |
Colonic Neoplasms/*pathology | 4 | 5.0 |
Head and Neck Neoplasms/*pathology | 6 | 28.0 |
*MAP Kinase Signaling System | 6 | 5.0 |
CHO Cells | 30 | 1.0 |
DNA, Complementary/metabolism | 16 | 1.0 |
MAP Kinase Signaling System | 13 | 4.0 |
*Membrane Proteins | 6 | 0.0 |
Plasmids/metabolism | 15 | 1.0 |
*Ubiquitin-Protein Ligases | 16 | 2.0 |
Cloning, Molecular | 39 | 0.0 |
DNA/biosynthesis | 17 | 2.0 |
Epidermal Growth Factor/metabolism/*physiology | 2 | 16.0 |
Epithelial Cells/*metabolism | 7 | 5.0 |
Thiophenes/pharmacology | 2 | 5.0 |
Trans-Activation (Genetics) | 31 | 1.0 |
U937 Cells | 3 | 0.0 |
Amino Acid Substitution | 5 | 0.0 |
Recombinant Proteins/metabolism | 26 | 1.0 |
Sequence Deletion | 21 | 1.0 |
Zinc/*pharmacology | 2 | 6.0 |
src-Family Kinases/*metabolism | 3 | 1.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 4 | 12.0 |
Chi-Square Distribution | 10 | 1.0 |
Genes, erbB-1 | 14 | 77.0 |
Paclitaxel/*therapeutic use | 2 | 13.0 |
Predictive Value of Tests | 46 | 2.0 |
Proliferating Cell Nuclear Antigen/analysis | 18 | 7.0 |
Receptor, erbB-2/analysis | 28 | 28.0 |
Receptors, Estrogen/analysis | 62 | 18.0 |
Receptors, Progesterone/analysis | 40 | 16.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/metabolism | 36 | 81.0 |
Cell Line, Transformed | 34 | 2.0 |
Fibroblasts/cytology | 4 | 1.0 |
Protein-Tyrosine-Phosphatase/antagonists & inhibitors/metabolism | 2 | 14.0 |
Signal Transduction/drug effects/*physiology | 12 | 5.0 |
Chemotherapy, Adjuvant | 6 | 2.0 |
Colorectal Neoplasms/*drug therapy | 4 | 33.0 |
Drug Design | 10 | 3.0 |
Endothelial Growth Factors/antagonists & inhibitors | 3 | 18.0 |
Immunotherapy/methods | 6 | 7.0 |
Infusions, Intravenous | 7 | 1.0 |
Isoenzymes/antagonists & inhibitors | 4 | 9.0 |
Lymphokines/antagonists & inhibitors | 2 | 12.0 |
Matrix Metalloproteinases/antagonists & inhibitors | 2 | 22.0 |
Prostaglandin-Endoperoxide Synthase | 6 | 20.0 |
Caveolins/metabolism | 2 | 10.0 |
Cell Aging/*physiology | 2 | 3.0 |
Down-Regulation/*physiology | 2 | 6.0 |
Nerve Tissue Proteins/genetics/metabolism | 2 | 2.0 |
Signal Transduction/physiology | 36 | 3.0 |
Carcinoma, Squamous Cell | 21 | 13.0 |
DNA-Binding Proteins/genetics/metabolism/*physiology | 2 | 3.0 |
Head and Neck Neoplasms | 5 | 45.0 |
*Milk Proteins | 6 | 1.0 |
Transforming Growth Factor alpha/metabolism | 39 | 54.0 |
Colonic Neoplasms | 3 | 2.0 |
Gene Expression | 100 | 1.0 |
Insulin-Like Growth Factor I/pharmacology | 3 | 1.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 25 | 49.0 |
Receptor, IGF Type 1/genetics/*metabolism | 2 | 33.0 |
S Phase | 15 | 4.0 |
Transforming Growth Factor alpha/*metabolism | 29 | 41.0 |
Isoenzymes/*biosynthesis | 5 | 7.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis | 5 | 11.0 |
Receptor, Epidermal Growth Factor/*biosynthesis | 77 | 66.0 |
Receptor, erbB-2/*biosynthesis | 17 | 34.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 6 | 3.0 |
Breast Neoplasms/pathology | 9 | 8.0 |
Carcinoma, Hepatocellular/pathology | 2 | 4.0 |
Cell Cycle/drug effects | 27 | 5.0 |
Drug Interactions | 6 | 0.0 |
Lung Neoplasms/pathology | 4 | 7.0 |
Epidermal Growth Factor/*antagonists & inhibitors | 10 | 45.0 |
Gene Expression Regulation, Neoplastic | 95 | 4.0 |
Receptor, Epidermal Growth Factor/drug effects/*metabolism | 11 | 20.0 |
Tumor Markers, Biological/*metabolism | 35 | 8.0 |
Adolescent | 114 | 0.0 |
Child, Preschool | 53 | 0.0 |
Glomerular Filtration Rate | 4 | 3.0 |
Infant | 27 | 0.0 |
Antibodies, Monoclonal/*adverse effects | 2 | 11.0 |
Incidence | 5 | 0.0 |
Regression Analysis | 19 | 1.0 |
Costs and Cost Analysis | 3 | 4.0 |
*Models, Theoretical | 3 | 5.0 |
Caveolae/metabolism | 2 | 25.0 |
Cell Division/physiology | 42 | 4.0 |
Cell Movement/physiology | 3 | 1.0 |
Cell Nucleus/physiology | 2 | 2.0 |
Cell Survival/physiology | 2 | 1.0 |
Estradiol/*metabolism | 2 | 3.0 |
Receptors, Estrogen/*physiology | 3 | 9.0 |
Signal Transduction/*physiology | 43 | 3.0 |
3T3 Cells | 61 | 2.0 |
DNA-Binding Proteins/antagonists & inhibitors/genetics/*metabolism | 2 | 9.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 71 | 5.0 |
*Neovascularization, Pathologic | 9 | 2.0 |
Promoter Regions (Genetics)/genetics | 6 | 0.0 |
Trans-Activators/antagonists & inhibitors/genetics/*metabolism | 3 | 21.0 |
*Up-Regulation | 3 | 1.0 |
Carbohydrate Sequence | 2 | 0.0 |
Cell Division/drug effects/physiology | 21 | 7.0 |
Dogs | 9 | 0.0 |
Structure-Activity Relationship | 55 | 1.0 |
Tumor Cells, Cultured/cytology/metabolism | 2 | 12.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 7 | 18.0 |
Keratinocytes/*metabolism/*pathology | 2 | 66.0 |
Neoplasm Invasiveness/*pathology | 3 | 11.0 |
Proteins/genetics/*metabolism | 4 | 0.0 |
Bladder Neoplasms/genetics/*pathology | 3 | 50.0 |
Genes, ras/genetics | 3 | 2.0 |
Loss of Heterozygosity | 27 | 3.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Mutation | 103 | 1.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Protein p16/genetics | 7 | 8.0 |
Protein p53/genetics | 11 | 6.0 |
DNA-Binding Proteins/metabolism | 17 | 0.0 |
Flavonoids/pharmacology | 16 | 4.0 |
*I-kappa B | 2 | 1.0 |
MAP Kinase Kinase 1 | 8 | 4.0 |
MAP Kinase Kinase 2 | 2 | 4.0 |
MAP Kinase Signaling System/drug effects/*physiology | 3 | 7.0 |
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | 2 | 4.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 5 | 5.0 |
Proto-Oncogene Protein p21(ras)/*metabolism | 3 | 6.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*metabolism | 17 | 51.0 |
Zinc/pharmacology | 2 | 3.0 |
Epidermal Growth Factor/*physiology | 16 | 11.0 |
Prostatic Neoplasms/*metabolism | 5 | 4.0 |
Receptor, erbB-2/*metabolism | 43 | 28.0 |
Receptor, erbB-3/*metabolism | 9 | 42.0 |
Adenocarcinoma/*genetics | 6 | 4.0 |
Clone Cells | 9 | 0.0 |
DNA, Neoplasm/analysis | 37 | 4.0 |
*Genetic Heterogeneity | 3 | 2.0 |
Lymphatic Metastasis/*genetics | 3 | 21.0 |
Microsatellite Repeats | 10 | 0.0 |
Receptor, Epidermal Growth Factor/genetics | 59 | 53.0 |
Receptor, erbB-2/genetics | 4 | 21.0 |
Genotype | 12 | 0.0 |
Genes, erbB-1/genetics | 14 | 82.0 |
Down-Regulation/drug effects | 11 | 4.0 |
Signal Transduction/*drug effects | 24 | 6.0 |
Antibodies, Monoclonal/metabolism | 9 | 2.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
DNA/metabolism | 14 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 31 | 0.0 |
Gene Therapy/*methods | 17 | 4.0 |
*Gene Transfer Techniques | 8 | 2.0 |
Genetic Vectors/metabolism | 2 | 8.0 |
Microscopy, Confocal | 23 | 2.0 |
Promoter Regions (Genetics) | 33 | 0.0 |
Thymidine/metabolism | 15 | 4.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Chromosome Mapping | 26 | 0.0 |
*Disease Models, Animal | 4 | 1.0 |
Cell Survival/drug effects | 26 | 2.0 |
Flow Cytometry | 88 | 1.0 |
Head and Neck Neoplasms/*drug therapy/metabolism/pathology | 2 | 33.0 |
Mitogen-Activated Protein Kinase 8 | 2 | 2.0 |
Signal Transduction/drug effects | 46 | 6.0 |
Axilla | 8 | 12.0 |
Case-Control Studies | 30 | 0.0 |
In Situ Hybridization | 29 | 1.0 |
*Nucleoside-Diphosphate Kinase | 3 | 4.0 |
Apoptosis/drug effects/physiology | 4 | 4.0 |
Breast Neoplasms/*drug therapy/metabolism | 10 | 37.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Enzyme Inhibitors/*therapeutic use | 18 | 19.0 |
Fibroblast Growth Factor 2/metabolism | 6 | 6.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 8 | 19.0 |
Quinazolines/*therapeutic use | 27 | 75.0 |
*Taxoids | 6 | 10.0 |
Tumor Cells, Cultured/drug effects/metabolism | 13 | 6.0 |
Antibody Specificity | 13 | 0.0 |
Microscopy, Electron | 11 | 0.0 |
Receptor, Epidermal Growth Factor/*genetics/*immunology | 2 | 100.0 |
Antibodies, Monoclonal/*diagnostic use | 4 | 1.0 |
Neoplasms/drug therapy/immunology | 2 | 28.0 |
Receptor, Epidermal Growth Factor/*antagonists & | 4 | 100.0 |
Estrogen Antagonists/*therapeutic use | 2 | 10.0 |
Quinazolines/therapeutic use | 15 | 88.0 |
Tamoxifen/*therapeutic use | 7 | 8.0 |
Head and Neck Neoplasms/*drug therapy/*radiotherapy | 2 | 66.0 |
Antineoplastic Agents/pharmacology/therapeutic use | 6 | 19.0 |
Enzyme Inhibitors/pharmacology/therapeutic use | 2 | 10.0 |
Quinazolines/pharmacology/therapeutic use | 6 | 75.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/immunology | 7 | 87.0 |
Cell Differentiation/drug effects | 7 | 0.0 |
Breast Neoplasms/*genetics | 5 | 0.0 |
Estrogens/*physiology | 2 | 5.0 |
MAP Kinase Signaling System/physiology | 8 | 10.0 |
Receptors, Cell Surface/*genetics | 4 | 1.0 |
MAP Kinase Signaling System/*drug effects | 5 | 13.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 11 | 4.0 |
Receptor, Insulin/metabolism | 3 | 3.0 |
Receptors, Fibroblast Growth Factor/metabolism | 3 | 6.0 |
Receptors, Platelet-Derived Growth Factor/metabolism | 9 | 20.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 5 | 5.0 |
Carcinoma, Squamous Cell/metabolism/pathology/*radiotherapy | 2 | 100.0 |
Cell Division/radiation effects | 6 | 12.0 |
Chromones/pharmacology | 12 | 5.0 |
Dose-Response Relationship, Radiation | 12 | 3.0 |
Morpholines/pharmacology | 14 | 5.0 |
Oropharyngeal Neoplasms/metabolism/pathology/*radiotherapy | 2 | 100.0 |
Radiation Tolerance | 7 | 7.0 |
Neoplasms/drug therapy | 3 | 5.0 |
Cell Cycle | 14 | 1.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/physiology | 2 | 50.0 |
Smoking/adverse effects | 3 | 1.0 |
Antigens, CD44/*metabolism | 2 | 1.0 |
Breast/cytology/*metabolism | 3 | 12.0 |
Breast Neoplasms/*metabolism/pathology | 19 | 10.0 |
Epithelial Cells/cytology/metabolism | 2 | 3.0 |
Adenocarcinoma/*metabolism/*pathology | 3 | 21.0 |
Cell Adhesion Molecules/*biosynthesis | 2 | 2.0 |
Cell Movement | 28 | 3.0 |
Epidermal Growth Factor/antagonists & inhibitors/*metabolism | 2 | 28.0 |
Fibroblasts/metabolism | 12 | 1.0 |
Lung/cytology/*metabolism | 2 | 6.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 13 | 11.0 |
RNA, Messenger/genetics | 34 | 1.0 |
Rats, Sprague-Dawley | 15 | 0.0 |
Bladder Neoplasms/*metabolism/pathology | 2 | 6.0 |
Neovascularization, Pathologic/*metabolism/pathology | 2 | 4.0 |
Breast Neoplasms/metabolism | 8 | 6.0 |
Cell Death/drug effects/physiology | 2 | 4.0 |
Estrogens/physiology | 2 | 6.0 |
Response Elements/physiology | 2 | 6.0 |
Trans-Activation (Genetics)/drug effects/physiology | 3 | 15.0 |
Tyrosine/*metabolism | 20 | 6.0 |
Breast Neoplasms/*genetics/*pathology | 2 | 3.0 |
RNA, Messenger/biosynthesis | 20 | 1.0 |
src-Family Kinases/antagonists & inhibitors | 3 | 15.0 |
Ki-67 Antigen/metabolism | 15 | 6.0 |
Papillomavirus, Human/genetics/*metabolism | 2 | 22.0 |
*Ploidies | 8 | 11.0 |
Binding, Competitive | 30 | 1.0 |
Receptor, Epidermal Growth Factor/*analysis/*metabolism | 2 | 100.0 |
Age Factors | 26 | 1.0 |
Administration, Oral | 12 | 1.0 |
Biological Availability | 2 | 0.0 |
Enzyme Inhibitors/*chemical synthesis/pharmacology | 4 | 22.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors | 9 | 20.0 |
Vascular Endothelial Growth Factor Receptor-1 | 2 | 0.0 |
Adenocarcinoma/chemistry/pathology | 5 | 29.0 |
CA-125 Antigen/analysis | 2 | 10.0 |
Carcinoma, Non-Small-Cell Lung/*chemistry/pathology | 2 | 50.0 |
Carcinoma, Squamous Cell/chemistry/pathology | 3 | 27.0 |
Cathepsin D/analysis | 11 | 32.0 |
Cytosol/*chemistry | 2 | 22.0 |
Lung Neoplasms/*chemistry/pathology | 3 | 17.0 |
Proteins/*analysis | 3 | 2.0 |
Antibodies, Monoclonal/adverse effects/therapeutic use | 2 | 22.0 |
In Situ Nick-End Labeling | 12 | 2.0 |
Epidermal Growth Factor/*analysis | 23 | 19.0 |
Fatal Outcome | 6 | 1.0 |
Tumor Markers, Biological/*blood | 9 | 1.0 |
Colonic Neoplasms/*metabolism | 6 | 7.0 |
MAP Kinase Signaling System/*physiology | 5 | 5.0 |
Matrix Metalloproteinases/metabolism | 3 | 6.0 |
Trans-Activation (Genetics)/*physiology | 5 | 4.0 |
Biological Markers | 10 | 0.0 |
Mice, Inbred C3H | 6 | 0.0 |
*Muscle Proteins | 6 | 2.0 |
Radiation Tolerance/*physiology | 2 | 14.0 |
Radiobiology | 5 | 38.0 |
Receptor, Epidermal Growth Factor/metabolism/radiation effects | 2 | 66.0 |
Tumor Markers, Biological/*biosynthesis | 7 | 8.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Endosomes/*metabolism | 8 | 7.0 |
Protein Transport | 13 | 2.0 |
Receptor, Epidermal Growth Factor/*metabolism/physiology | 4 | 40.0 |
Signal Transduction/radiation effects | 2 | 22.0 |
*Ultraviolet Rays | 6 | 2.0 |
Cell Membrane/metabolism/ultrastructure | 4 | 6.0 |
Cysteine Proteinase Inhibitors/pharmacology | 5 | 2.0 |
Endopeptidases/metabolism | 4 | 2.0 |
Epidermal Growth Factor/*pharmacology | 61 | 7.0 |
Leupeptins/pharmacology | 2 | 1.0 |
Protease Inhibitors/pharmacology | 9 | 4.0 |
Proteasome Endopeptidase Complex | 8 | 1.0 |
Protein Transport/*physiology | 4 | 8.0 |
Proto-Oncogene Proteins/metabolism/pharmacology | 3 | 50.0 |
Ubiquitins/*metabolism | 3 | 1.0 |
Breast Neoplasms/*metabolism/*pathology | 6 | 16.0 |
Receptor, erbB-2/*antagonists & inhibitors | 6 | 40.0 |
Gene Targeting | 6 | 1.0 |
Gene Therapy | 7 | 2.0 |
*Genetic Vectors | 7 | 2.0 |
Luminescent Proteins/genetics | 3 | 1.0 |
Receptors, Estrogen/*analysis | 40 | 15.0 |
Carcinoma/*metabolism/pathology | 7 | 11.0 |
Adenoma/*chemistry/pathology | 3 | 21.0 |
Carcinoembryonic Antigen/genetics | 2 | 16.0 |
Carcinoma, Ductal, Breast/genetics/metabolism/pathology | 2 | 16.0 |
Keratin/genetics | 3 | 6.0 |
Neoplasm Proteins/*genetics | 6 | 0.0 |
Neoplasm, Residual | 4 | 4.0 |
Proteins/*genetics | 4 | 0.0 |
Tumor Markers, Biological/*genetics | 8 | 7.0 |
Angiogenesis Inhibitors/therapeutic use | 6 | 19.0 |
Antineoplastic Agents/therapeutic use | 23 | 8.0 |
Immunotherapy | 7 | 2.0 |
Interferons/therapeutic use | 2 | 6.0 |
Receptor, Epidermal Growth Factor | 17 | 6.0 |
Carcinoma/*genetics | 3 | 2.0 |
*Genetic Techniques | 2 | 3.0 |
In Situ Hybridization, Fluorescence | 31 | 1.0 |
Oncogenes/*genetics | 9 | 11.0 |
Receptor, Epidermal Growth Factor/biosynthesis | 22 | 47.0 |
Receptor, erbB-2/biosynthesis | 8 | 32.0 |
Autocrine Communication/*physiology | 6 | 21.0 |
Mathematics | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*physiology | 13 | 8.0 |
*Immediate-Early Proteins | 3 | 1.0 |
KB Cells | 3 | 3.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/genetics | 23 | 71.0 |
Breast Neoplasms/*chemistry | 17 | 23.0 |
Iodine Radioisotopes/diagnostic use | 10 | 3.0 |
Radioligand Assay | 31 | 6.0 |
*Endocytosis | 8 | 4.0 |
Proteins/*physiology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/*genetics/physiology | 2 | 25.0 |
Ubiquitins/metabolism | 2 | 1.0 |
In Vitro | 31 | 0.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/immunology | 3 | 100.0 |
Tetradecanoylphorbol Acetate/pharmacology | 14 | 0.0 |
Angiogenesis Inhibitors/pharmacology/therapeutic use | 2 | 22.0 |
Antineoplastic Agents/pharmacology/*therapeutic use | 7 | 20.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
Neovascularization, Pathologic/*drug therapy | 5 | 12.0 |
Protein Kinase Inhibitors/pharmacology/therapeutic use | 2 | 100.0 |
Quinazolines/pharmacology/*therapeutic use | 5 | 83.0 |
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors | 2 | 25.0 |
Signal Transduction/drug effects/physiology | 21 | 8.0 |
Alkylating Agents/pharmacology | 2 | 5.0 |
*Alleles | 6 | 0.0 |
Amino Acid Motifs | 3 | 0.0 |
Ethylnitrosourea | 3 | 25.0 |
Genes, Dominant | 13 | 1.0 |
Genetic Complementation Test | 2 | 0.0 |
Heterozygote | 8 | 0.0 |
Mice, Inbred C57BL | 18 | 0.0 |
Point Mutation | 14 | 0.0 |
Protein Structure, Secondary | 6 | 0.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 6 | 8.0 |
Sequence Homology, Amino Acid | 23 | 0.0 |
Gene Expression Profiling | 9 | 0.0 |
Lung Neoplasms/*genetics/*pathology | 2 | 15.0 |
Cell Division/*drug effects | 11 | 3.0 |
DNA Damage | 6 | 0.0 |
Vulvar Neoplasms | 2 | 28.0 |
Apoptosis/physiology | 7 | 2.0 |
Cell Movement/*physiology | 7 | 3.0 |
DNA Fragmentation | 6 | 1.0 |
Enzyme Inhibitors/metabolism | 7 | 3.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 13 | 5.0 |
Tumor Necrosis Factor-alpha/metabolism | 13 | 1.0 |
Metaplasia | 8 | 8.0 |
Mucins/metabolism | 4 | 8.0 |
Protein-Tyrosine Kinase | 5 | 14.0 |
Brain Neoplasms/genetics/*pathology/surgery | 2 | 100.0 |
Epidermal Growth Factor/*biosynthesis | 8 | 27.0 |
Fetus | 3 | 0.0 |
Transforming Growth Factor alpha/*biosynthesis | 15 | 71.0 |
Biopsy | 31 | 1.0 |
Phosphoric Monoester Hydrolases/genetics/metabolism | 4 | 18.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
Tumor Suppressor Proteins/genetics/metabolism | 4 | 12.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 2 | 1.0 |
Colony-Forming Units Assay | 3 | 0.0 |
Mutagenesis | 11 | 1.0 |
Osteosarcoma | 2 | 2.0 |
P-Glycoprotein/genetics | 2 | 6.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Cell Transformation, Neoplastic | 18 | 3.0 |
Cisplatin/therapeutic use | 4 | 10.0 |
Combined Modality Therapy/methods | 4 | 23.0 |
DNA Repair/drug effects/radiation effects | 2 | 100.0 |
Deoxycytidine/*analogs & derivatives/therapeutic use | 2 | 18.0 |
Neovascularization, Pathologic | 16 | 4.0 |
Paclitaxel/*analogs & derivatives/therapeutic use | 2 | 66.0 |
Neoplasms/*drug therapy/*radiotherapy | 4 | 80.0 |
Alleles | 13 | 0.0 |
Astrocytoma/*genetics/pathology | 5 | 21.0 |
Brain Neoplasms/*genetics/pathology | 17 | 24.0 |
Chromosomes, Human, Pair 10/*genetics | 3 | 2.0 |
Cyclin-Dependent Kinases/genetics | 9 | 15.0 |
Molecular Biology | 6 | 2.0 |
Oligodendroglioma/*genetics/pathology | 2 | 16.0 |
*Proto-Oncogene Proteins | 15 | 0.0 |
Tumor Markers, Biological/genetics | 5 | 5.0 |
Cell Transformation, Neoplastic/drug effects | 2 | 5.0 |
DNA Primers/chemistry | 13 | 1.0 |
Gene Expression Regulation/*drug effects | 5 | 0.0 |
Mitosis | 8 | 1.0 |
Phosphotyrosine/metabolism | 31 | 7.0 |
Receptor, Epidermal Growth Factor/*genetics/metabolism | 28 | 53.0 |
Epithelium/chemistry | 5 | 4.0 |
Receptor, erbB-3/*analysis | 2 | 40.0 |
Transforming Growth Factor alpha/*analysis | 21 | 41.0 |
Breast Neoplasms | 15 | 5.0 |
Cell Membrane/metabolism | 54 | 3.0 |
Cytosol/metabolism | 11 | 2.0 |
Endocytosis | 21 | 5.0 |
Gene Expression Regulation | 32 | 0.0 |
Proto-Oncogene Proteins c-raf/*metabolism | 2 | 5.0 |
Receptor, Epidermal Growth Factor/*chemistry/*metabolism | 4 | 44.0 |
Papillomavirus, Human/isolation & purification | 4 | 16.0 |
Epidermal Growth Factor/*chemistry/*metabolism | 2 | 50.0 |
Models, Chemical | 5 | 1.0 |
Retinoids/*metabolism | 2 | 18.0 |
Tretinoin/pharmacology | 6 | 1.0 |
Cell Nucleus/ultrastructure | 4 | 3.0 |
*Gene Dosage | 2 | 2.0 |
*Gene Duplication | 4 | 2.0 |
Gene Frequency | 7 | 0.0 |
In Situ Hybridization, Fluorescence/*methods | 7 | 8.0 |
Interphase | 4 | 2.0 |
Polymerase Chain Reaction/*methods | 6 | 1.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 3 | 6.0 |
Antigens, CD3/*immunology | 5 | 4.0 |
Cytotoxicity, Immunologic | 3 | 0.0 |
Organ Culture Techniques | 3 | 0.0 |
Placenta/*metabolism | 6 | 3.0 |
Cell Division/genetics | 10 | 2.0 |
DNA, Complementary/genetics | 9 | 0.0 |
Gene Deletion | 36 | 1.0 |
Plasmids/genetics | 4 | 0.0 |
Viral Matrix Proteins/genetics/*physiology | 2 | 25.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 49 | 31.0 |
RNA/metabolism | 2 | 0.0 |
Tetracycline/pharmacology | 5 | 6.0 |
Glioblastoma/*genetics/pathology | 11 | 47.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*genetics | 21 | 84.0 |
Transforming Growth Factor alpha/biosynthesis/*genetics | 3 | 100.0 |
*Apoptosis | 23 | 1.0 |
Rats, Nude | 5 | 10.0 |
Fluorescent Antibody Technique, Indirect | 12 | 1.0 |
Receptor, Epidermal Growth Factor/*analysis/physiology | 5 | 71.0 |
*Chromosomes, Human, Pair 10 | 8 | 4.0 |
*Chromosomes, Human, Pair 17 | 5 | 0.0 |
Gene Amplification | 62 | 8.0 |
*Genes, erbB-1 | 15 | 88.0 |
Glioma/*genetics | 20 | 26.0 |
*Loss of Heterozygosity | 2 | 0.0 |
*ADP Ribose Transferases | 7 | 9.0 |
*Bacterial Toxins | 5 | 3.0 |
Cell Survival | 20 | 1.0 |
Culture Media, Serum-Free/metabolism | 2 | 40.0 |
Dimerization | 34 | 2.0 |
*Virulence Factors | 9 | 10.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Carcinoma, Small Cell/*genetics/metabolism/pathology | 2 | 50.0 |
Cell Communication | 6 | 2.0 |
Doxycycline/pharmacology | 2 | 3.0 |
Lung Neoplasms/*genetics/metabolism/pathology | 3 | 13.0 |
RNA, Messenger/analysis | 50 | 1.0 |
*Aneuploidy | 6 | 6.0 |
*Chromosomes, Human, Pair 7 | 12 | 4.0 |
Genes, erbB-2/*genetics | 9 | 24.0 |
MAP Kinase Signaling System/drug effects | 8 | 8.0 |
Neoplasms/drug therapy/*metabolism | 2 | 11.0 |
Statistics, Nonparametric | 4 | 0.0 |
Breast/*cytology | 6 | 17.0 |
Culture Media, Serum-Free | 9 | 2.0 |
Fluorescent Dyes | 7 | 1.0 |
Carcinoma, Squamous Cell/*metabolism | 17 | 16.0 |
Head and Neck Neoplasms/*metabolism | 6 | 28.0 |
Matrix Metalloproteinases/*metabolism | 6 | 15.0 |
Neoplasm Proteins/*metabolism | 31 | 6.0 |
Statistics | 6 | 1.0 |
Phosphodiesterase Inhibitors/pharmacology | 4 | 3.0 |
Sequence Alignment | 13 | 0.0 |
Cell Cycle/*drug effects | 4 | 2.0 |
Epidermal Growth Factor/*drug effects | 2 | 66.0 |
Estrogens | 3 | 13.0 |
Neoplasm Recurrence, Local/prevention & control | 2 | 16.0 |
Postmenopause | 8 | 4.0 |
Tumor Cells, Cultured/drug effects | 28 | 4.0 |
Epitopes | 6 | 0.0 |
Genetic Vectors | 21 | 1.0 |
Peptides/chemistry | 5 | 1.0 |
Tyrosine/chemistry/metabolism | 2 | 11.0 |
*Genes, erbB-2 | 13 | 15.0 |
Ovarian Neoplasms | 3 | 8.0 |
Receptor, erbB-2 | 64 | 39.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 8 | 3.0 |
Receptor, Epidermal Growth Factor/drug effects/*physiology | 10 | 66.0 |
Ovarian Neoplasms/*drug therapy/pathology | 4 | 16.0 |
Quinazolines/administration & dosage/*therapeutic use | 3 | 100.0 |
Antineoplastic Agents/administration & dosage/*pharmacology | 4 | 23.0 |
Antineoplastic Combined Chemotherapy Protocols/pharmacology | 3 | 16.0 |
Enzyme Inhibitors/administration & dosage/*pharmacology | 2 | 12.0 |
Quinazolines/administration & dosage/*pharmacology | 3 | 100.0 |
RNA, Neoplasm/genetics | 15 | 4.0 |
Receptor, erbB-2/genetics/metabolism | 4 | 26.0 |
Receptor, erbB-3/genetics/metabolism | 2 | 50.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 9 | 9.0 |
Carcinoma, Squamous Cell/drug therapy/*metabolism/pathology | 2 | 33.0 |
Epidermal Growth Factor/*metabolism/pharmacology | 10 | 16.0 |
Neoplasms, Experimental/*drug therapy/pathology | 2 | 22.0 |
Quinazolines/*pharmacology/therapeutic use | 3 | 50.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Dactinomycin/pharmacology | 4 | 1.0 |
Lysophospholipids/*pharmacology | 3 | 8.0 |
Mitogens/pharmacology | 5 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Carcinoma, Squamous Cell/genetics/*metabolism | 5 | 25.0 |
Liver/metabolism | 10 | 1.0 |
Reference Values | 33 | 0.0 |
Genes, src | 4 | 17.0 |
Epidermal Growth Factor/physiology | 5 | 5.0 |
*Papillomavirus, Human | 2 | 6.0 |
Gestational Age | 7 | 0.0 |
Placenta/metabolism | 7 | 3.0 |
Uterine Neoplasms/*metabolism | 3 | 9.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Comet Assay | 3 | 4.0 |
DNA, Neoplasm/drug effects | 2 | 6.0 |
*Drug Delivery Systems | 2 | 6.0 |
Brain Neoplasms/*metabolism | 8 | 10.0 |
Glioma/*metabolism | 5 | 10.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Fluorescent Antibody Technique | 18 | 0.0 |
Angiogenesis Inhibitors/pharmacology | 3 | 8.0 |
Apoptosis/*drug effects | 14 | 1.0 |
Cyclooxygenase Inhibitors/pharmacology | 3 | 4.0 |
Immunoprecipitation | 11 | 5.0 |
Isoenzymes/*antagonists & inhibitors | 2 | 6.0 |
Lymphatic Metastasis/pathology | 3 | 4.0 |
Pyrazoles/pharmacology | 6 | 12.0 |
Sulfonamides/pharmacology | 5 | 4.0 |
Tumor Stem Cell Assay | 11 | 5.0 |
DNA Repair | 6 | 0.0 |
Mitogen-Activated Protein Kinase 3/metabolism | 4 | 11.0 |
Radiation, Ionizing | 9 | 6.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 5 | 6.0 |
*Gene Amplification | 52 | 13.0 |
Premenopause | 6 | 6.0 |
Receptor, erbB-2/*genetics/metabolism | 3 | 30.0 |
Receptors, Estrogen/*metabolism | 11 | 5.0 |
Questionnaires | 2 | 0.0 |
Recurrence | 19 | 1.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 7 | 10.0 |
*Gene Expression Profiling | 6 | 1.0 |
Head and Neck Neoplasms/*genetics/pathology | 2 | 6.0 |
Keratinocytes | 3 | 8.0 |
Neoplasm Proteins/*biosynthesis | 3 | 3.0 |
Stimulation, Chemical | 3 | 0.0 |
Suramin/*pharmacology | 3 | 14.0 |
Testosterone/pharmacology | 2 | 3.0 |
Antibodies, Bispecific/therapeutic use | 2 | 50.0 |
Immunotoxins/therapeutic use | 2 | 20.0 |
Neoplasms/*drug therapy | 10 | 8.0 |
Research Design | 2 | 2.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/metabolism | 9 | 56.0 |
Receptor, Epidermal Growth Factor/immunology/*metabolism | 14 | 58.0 |
Transforming Growth Factor alpha/immunology/*metabolism | 5 | 83.0 |
Cell Movement/drug effects/physiology | 2 | 3.0 |
Cyclins/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 5 | 7.0 |
Receptor, erbB-2/*antagonists & inhibitors/metabolism | 6 | 75.0 |
Active Transport, Cell Nucleus | 3 | 1.0 |
Carcinogens | 2 | 2.0 |
Epithelium/drug effects/metabolism | 3 | 5.0 |
Receptor, Epidermal Growth Factor/*chemistry | 8 | 53.0 |
Transcription Factor AP-1/metabolism | 6 | 2.0 |
Tyrosine/chemistry | 9 | 6.0 |
Age of Onset | 2 | 0.0 |
Mouth Mucosa/pathology | 2 | 8.0 |
Smoking | 2 | 0.0 |
Gelatinase A/analysis | 2 | 18.0 |
Gelatinase B/analysis | 2 | 11.0 |
Genes, erbB-2 | 13 | 16.0 |
Microcirculation | 3 | 1.0 |
Neoplasm Staging/*methods | 2 | 5.0 |
Carcinoma, Renal Cell/*genetics | 2 | 2.0 |
DNA Primers | 32 | 0.0 |
Kidney Neoplasms/*genetics | 4 | 1.0 |
Neoplasm Staging/methods | 2 | 6.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 3 | 1.0 |
Receptors, Estrogen/metabolism | 26 | 8.0 |
Receptors, Progesterone/metabolism | 22 | 11.0 |
*Epidermal Growth Factor | 3 | 6.0 |
Membrane Proteins/chemistry/genetics/*metabolism | 4 | 6.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Aneuploidy | 15 | 7.0 |
Breast Neoplasms/chemistry/*pathology | 5 | 29.0 |
Carcinoma, Ductal, Breast/chemistry/*pathology | 2 | 50.0 |
Cytoplasm/chemistry | 7 | 3.0 |
Hyaluronic Acid/*analysis | 2 | 10.0 |
Membrane Proteins/analysis | 2 | 1.0 |
Tissue Plasminogen Activator/analysis | 2 | 5.0 |
Cell Size | 6 | 2.0 |
Carcinoma, Squamous Cell/*genetics/*pathology | 4 | 36.0 |
Receptor, Epidermal Growth Factor/analysis/*biosynthesis | 15 | 68.0 |
Drug Evaluation, Preclinical | 5 | 2.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Mucins/*biosynthesis/genetics | 3 | 13.0 |
Transforming Growth Factor alpha/physiology | 5 | 19.0 |
Drosophila | 4 | 1.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 3 | 3.0 |
Plasmids | 6 | 0.0 |
Receptor, erbB-2/genetics/*metabolism | 8 | 24.0 |
Tumor Cells, Cultured/radiation effects | 4 | 10.0 |
Adenosine Triphosphate/metabolism | 12 | 2.0 |
Cations, Divalent/metabolism | 2 | 13.0 |
Molecular Structure | 16 | 2.0 |
Neuregulin-1/*metabolism | 4 | 28.0 |
Protein-Serine-Threonine Kinases/metabolism | 21 | 2.0 |
Cell Differentiation | 45 | 1.0 |
Epithelial Cells/pathology | 5 | 6.0 |
Mucins/*biosynthesis | 2 | 5.0 |
Tobacco | 2 | 7.0 |
Antigens, CD/genetics/physiology | 2 | 12.0 |
Extracellular Matrix Proteins/physiology | 2 | 14.0 |
Transforming Growth Factor alpha/*physiology | 6 | 28.0 |
Stomach Neoplasms/*chemistry/pathology | 3 | 21.0 |
Transforming Growth Factor alpha/analysis | 14 | 43.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/physiology | 13 | 86.0 |
Logistic Models | 5 | 0.0 |
Carcinoma, Squamous Cell/*chemistry/pathology | 7 | 30.0 |
Mouth Neoplasms/*chemistry/pathology | 4 | 44.0 |
Receptor Protein-Tyrosine Kinases/*analysis | 3 | 6.0 |
Receptor, erbB-3/analysis | 3 | 75.0 |
Antibodies | 4 | 0.0 |
Codon/genetics | 3 | 0.0 |
Genetic Markers | 15 | 0.0 |
Phosphoric Monoester Hydrolases/*genetics | 8 | 3.0 |
Tumor Suppressor Proteins/*genetics | 3 | 2.0 |
Keratinocytes/enzymology | 2 | 13.0 |
*Prognosis | 2 | 22.0 |
Receptors, Bombesin/metabolism | 2 | 28.0 |
src-Family Kinases/antagonists & inhibitors/*metabolism | 2 | 11.0 |
Tumor Markers, Biological | 20 | 4.0 |
Antigens, Neoplasm/*immunology | 5 | 3.0 |
Cancer Vaccines/*immunology | 2 | 3.0 |
*Immunotherapy | 5 | 3.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Biotransformation | 3 | 0.0 |
Epithelial Cells | 13 | 2.0 |
Receptor, Epidermal Growth Factor/*analysis/genetics | 22 | 57.0 |
Cervix Neoplasms/*metabolism | 3 | 9.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*metabolism | 11 | 50.0 |
Gastric Mucosa/pathology | 3 | 7.0 |
*Genes, ras | 8 | 3.0 |
Drug Administration Schedule | 13 | 1.0 |
Enzyme Inhibitors/administration & dosage | 2 | 15.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Epithelial Cells/cytology/drug effects/metabolism | 4 | 16.0 |
Transforming Growth Factor beta/pharmacology | 3 | 0.0 |
Neoplasms/*metabolism | 3 | 3.0 |
Morphogenesis | 5 | 2.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Neoplasms/physiopathology/therapy | 2 | 100.0 |
Antibodies, Monoclonal/immunology/therapeutic use | 2 | 10.0 |
Proliferating Cell Nuclear Antigen/metabolism | 10 | 4.0 |
Antibodies, Monoclonal/*therapeutic use | 28 | 8.0 |
Thromboplastin/*biosynthesis | 2 | 2.0 |
Chromosomes, Human, Pair 7/*genetics | 6 | 5.0 |
Conserved Sequence | 7 | 0.0 |
*Tumor Suppressor Proteins | 28 | 2.0 |
Chromosomes, Human, Pair 1 | 4 | 1.0 |
Chromosomes, Human, Pair 10 | 9 | 7.0 |
Chromosomes, Human, Pair 19 | 3 | 1.0 |
Genes, p16/genetics | 3 | 13.0 |
Genes, p53/genetics | 13 | 5.0 |
Phosphoric Monoester Hydrolases/genetics | 13 | 17.0 |
Tumor Cells, Cultured/metabolism | 8 | 4.0 |
Drug Screening Assays, Antitumor | 28 | 8.0 |
Growth Inhibitors/pharmacology | 4 | 2.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 5 | 5.0 |
Antibodies, Monoclonal/administration & dosage | 3 | 10.0 |
Protein Kinases/*metabolism | 6 | 1.0 |
Receptor, erbB-3/metabolism | 9 | 31.0 |
Keratinocytes/cytology | 5 | 14.0 |
Antigens, CD29/metabolism | 3 | 5.0 |
Isoenzymes/*metabolism | 4 | 1.0 |
Phospholipase C/*metabolism | 6 | 5.0 |
Colorectal Neoplasms/*pathology | 2 | 3.0 |
*Antigens, Nuclear | 2 | 1.0 |
*DNA Helicases | 2 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Genes, p53/physiology | 2 | 7.0 |
Introns/genetics | 4 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Colonic Neoplasms/*metabolism/mortality/pathology | 2 | 100.0 |
Cytoplasm/metabolism | 23 | 2.0 |
Neoplasm Proteins/*antagonists & inhibitors | 5 | 38.0 |
Radiotherapy Dosage | 9 | 6.0 |
Genes, p53/*genetics | 10 | 3.0 |
Cell Survival/drug effects/*genetics | 2 | 33.0 |
Cisplatin/*pharmacology | 5 | 3.0 |
Gene Expression Regulation, Neoplastic/drug effects | 18 | 4.0 |
Mutation/*genetics | 6 | 0.0 |
Protein-Tyrosine-Phosphatase/*antagonists & inhibitors | 3 | 15.0 |
Receptor, Epidermal Growth Factor/drug effects/*genetics | 3 | 50.0 |
Carcinoma, Squamous Cell/*genetics | 14 | 8.0 |
Cell Transformation, Neoplastic/genetics | 11 | 4.0 |
Mouth Neoplasms/*genetics | 5 | 10.0 |
DNA, Complementary | 12 | 0.0 |
Estradiol/*pharmacology | 6 | 2.0 |
Receptors, Estrogen/*genetics/physiology | 2 | 50.0 |
*Transfection | 4 | 1.0 |
Image Processing, Computer-Assisted | 17 | 4.0 |
Subcellular Fractions | 2 | 1.0 |
Monensin/pharmacology | 2 | 3.0 |
rab5 GTP-Binding Proteins/*metabolism | 4 | 33.0 |
Carcinoma/*metabolism | 8 | 9.0 |
Receptors, Androgen/*biosynthesis | 2 | 10.0 |
*Chromosome Aberrations | 15 | 2.0 |
Glioblastoma/*genetics/*pathology | 4 | 57.0 |
Cell Cycle/physiology | 6 | 1.0 |
*Cell Proliferation | 2 | 12.0 |
*Cell Survival | 2 | 5.0 |
Fibroblasts/cytology/physiology | 2 | 2.0 |
Lysophospholipids/metabolism | 2 | 11.0 |
Metalloendopeptidases/genetics/*metabolism | 5 | 14.0 |
Neoplasms/*radiotherapy | 3 | 25.0 |
Breast Neoplasms/*chemistry/pathology | 13 | 22.0 |
Anoxia | 3 | 3.0 |
Neoplasms/drug therapy/pathology | 2 | 28.0 |
Paclitaxel/*pharmacology | 3 | 4.0 |
Taxoids/*pharmacology | 2 | 40.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
*Protein Kinase Inhibitors | 2 | 3.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*genetics | 3 | 50.0 |
Caspases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Intracellular Membranes/metabolism | 3 | 1.0 |
Membrane Glycoproteins/genetics/metabolism | 2 | 2.0 |
Membrane Potentials/drug effects | 2 | 1.0 |
Permeability | 2 | 1.0 |
Cell Transformation, Neoplastic/*genetics | 7 | 3.0 |
Cyclins/genetics | 2 | 1.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Genes, p16 | 11 | 11.0 |
Glioblastoma/genetics/pathology | 4 | 28.0 |
Receptor, Epidermal Growth Factor/genetics/physiology | 6 | 54.0 |
Age Distribution | 3 | 0.0 |
Neoplasm Proteins/genetics/physiology | 2 | 10.0 |
*Nuclear Proteins | 19 | 1.0 |
Protein p53/physiology | 6 | 7.0 |
Proto-Oncogene Proteins/genetics/physiology | 2 | 6.0 |
Sex Distribution | 2 | 0.0 |
Animals, Newborn | 7 | 1.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Gene Expression Regulation, Developmental | 6 | 0.0 |
Metallothionein/genetics | 2 | 5.0 |
Mice, Transgenic | 26 | 0.0 |
Neck | 4 | 6.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Transgenes | 3 | 0.0 |
Phosphoproteins/*physiology | 2 | 2.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
Response Elements | 2 | 0.0 |
Trans-Activators/*physiology | 4 | 1.0 |
Transcription Factor, Sp1/metabolism | 5 | 1.0 |
Carcinoma, Squamous Cell/chemistry/pathology/ultrastructure | 2 | 100.0 |
Polyethylene Glycols/pharmacology | 2 | 4.0 |
Protein Denaturation | 2 | 0.0 |
Breast | 4 | 12.0 |
Cell Membrane/*metabolism | 12 | 4.0 |
Consensus Sequence | 4 | 0.0 |
Transcription Factors/*metabolism | 5 | 0.0 |
Uterus/cytology/metabolism | 2 | 50.0 |
Epithelial Cells/metabolism | 12 | 3.0 |
Glycoproteins/*metabolism | 4 | 2.0 |
Growth Substances/*metabolism | 12 | 8.0 |
Stromal Cells/metabolism | 4 | 4.0 |
Virus Replication | 6 | 0.0 |
Infant, Newborn | 11 | 0.0 |
Brain Neoplasms/*genetics/metabolism | 6 | 23.0 |
Glioblastoma/*genetics/metabolism | 2 | 16.0 |
Receptor, Epidermal Growth Factor/analysis/*genetics | 8 | 38.0 |
Cyclin D1/biosynthesis | 2 | 4.0 |
Growth Substances/*biosynthesis | 2 | 4.0 |
Protein p53/biosynthesis | 6 | 4.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Polymorphism, Restriction Fragment Length | 12 | 0.0 |
Restriction Mapping | 9 | 0.0 |
Astrocytoma/*genetics | 8 | 17.0 |
Glioblastoma/*genetics | 24 | 34.0 |
Prostatic Neoplasms/*drug therapy | 2 | 5.0 |
Receptor, Epidermal Growth Factor/*drug effects/physiology | 3 | 100.0 |
Neuregulin-1/pharmacology | 2 | 13.0 |
Karyotyping | 22 | 1.0 |
Keratinocytes/metabolism | 6 | 5.0 |
Receptor, erbB-3/*biosynthesis | 3 | 50.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Adenocarcinoma/*metabolism/pathology/therapy | 2 | 50.0 |
Cervix Neoplasms/*metabolism/pathology/therapy | 2 | 100.0 |
Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology | 5 | 17.0 |
Enzyme Inhibitors/*chemical synthesis/chemistry/pharmacology | 5 | 15.0 |
Fluorometry | 2 | 2.0 |
Magnetic Resonance Spectroscopy | 6 | 1.0 |
Quinazolines/*chemical synthesis/chemistry/pharmacology | 3 | 42.0 |
Epithelial Cells/cytology/drug effects | 2 | 8.0 |
Gene Library | 9 | 0.0 |
Genes, Wilms Tumor | 2 | 3.0 |
Growth Substances/genetics/*physiology | 2 | 11.0 |
Tumor Cells, Cultured/cytology/drug effects | 2 | 5.0 |
Staining and Labeling | 22 | 3.0 |
Endothelial Growth Factors/genetics | 2 | 2.0 |
Lymphokines/genetics | 2 | 2.0 |
Proto-Oncogene Proteins c-fos/genetics | 4 | 7.0 |
Proto-Oncogene Proteins c-jun/genetics | 2 | 5.0 |
*Phosphorylation | 2 | 14.0 |
Breast Neoplasms/metabolism/*pathology | 6 | 6.0 |
Catalase/metabolism | 2 | 3.0 |
Glutathione/metabolism | 3 | 1.0 |
Hydrogen Peroxide/*metabolism | 2 | 5.0 |
Oxidative Stress | 6 | 1.0 |
Reactive Oxygen Species | 3 | 2.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 5 | 3.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Lymph Node Excision | 3 | 4.0 |
Gene Expression Regulation, Neoplastic/physiology | 11 | 7.0 |
Adenocarcinoma/metabolism/secondary | 2 | 40.0 |
Lung Neoplasms/*metabolism/pathology | 6 | 8.0 |
Receptor, IGF Type 1/*metabolism | 2 | 5.0 |
Receptors, Platelet-Derived Growth Factor/*metabolism | 4 | 20.0 |
Anticarcinogenic Agents/*pharmacology | 7 | 7.0 |
Carcinoma, Squamous Cell/drug therapy/pathology | 5 | 71.0 |
DNA-Binding Proteins/physiology | 3 | 1.0 |
Head and Neck Neoplasms/drug therapy/pathology | 2 | 100.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*physiology | 6 | 66.0 |
Retinoid X Receptors | 2 | 0.0 |
Trans-Activators/physiology | 2 | 1.0 |
Transforming Growth Factor alpha/biosynthesis/*physiology | 2 | 50.0 |
Tumor Markers, Biological/biosynthesis | 2 | 5.0 |
Epidermal Growth Factor | 4 | 16.0 |
Glycoproteins/*biosynthesis | 3 | 6.0 |
Oncogene Proteins | 2 | 33.0 |
Antibodies, Monoclonal/pharmacology | 17 | 2.0 |
Carcinogenicity Tests | 4 | 5.0 |
Protein Conformation | 18 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/*drug effects/physiology | 2 | 100.0 |
Biopolymers | 4 | 3.0 |
Cell-Free System | 2 | 0.0 |
Inhibitory Concentration 50 | 14 | 4.0 |
Carcinoma, Squamous Cell/*drug therapy/metabolism/pathology | 3 | 60.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
Forskolin/pharmacology | 3 | 0.0 |
Protein Isoforms | 6 | 0.0 |
Protein Kinase C/metabolism | 13 | 2.0 |
Breast Neoplasms/*metabolism | 19 | 6.0 |
Receptors, Estrogen/genetics/metabolism | 3 | 9.0 |
Transforming Growth Factor alpha/pharmacology | 18 | 19.0 |
Biological Markers/*analysis | 3 | 2.0 |
Breast Neoplasms/*drug therapy/*metabolism | 3 | 15.0 |
Antibodies, Monoclonal/metabolism/*pharmacology | 2 | 28.0 |
Cell Division/drug effects/genetics | 8 | 9.0 |
Receptor, Epidermal Growth Factor/*genetics/immunology | 3 | 100.0 |
Cell Transformation, Neoplastic/genetics/*pathology | 2 | 18.0 |
Bladder Neoplasms/metabolism/*pathology | 2 | 14.0 |
Carcinoma, Transitional Cell/metabolism/*pathology | 2 | 20.0 |
Caco-2 Cells | 7 | 2.0 |
Intestinal Mucosa/*physiology | 2 | 7.0 |
Isoenzymes/*antagonists & inhibitors/genetics | 2 | 66.0 |
Microtubules/metabolism | 2 | 1.0 |
Phospholipase C/*antagonists & inhibitors/genetics | 2 | 100.0 |
Nasopharyngeal Neoplasms/metabolism/virology | 2 | 100.0 |
Protein p53/*metabolism | 12 | 2.0 |
*Antigens, Neoplasm | 2 | 1.0 |
Head and Neck Neoplasms/*genetics | 7 | 9.0 |
JNK Mitogen-Activated Protein Kinases | 10 | 1.0 |
ras Proteins/physiology | 2 | 6.0 |
DNA/chemistry | 3 | 1.0 |
Retroviridae/*genetics | 4 | 2.0 |
Epidermal Growth Factor/metabolism/pharmacology | 12 | 20.0 |
Mesocricetus | 4 | 2.0 |
Mitogens/metabolism/pharmacology | 2 | 50.0 |
*Chromosome Disorders | 3 | 4.0 |
Dissection | 3 | 14.0 |
Glioblastoma/genetics/*metabolism/pathology | 2 | 28.0 |
Antibodies, Monoclonal/pharmacology/therapeutic use | 7 | 43.0 |
Drug Delivery Systems | 7 | 7.0 |
Receptor, erbB-2/antagonists & inhibitors | 4 | 50.0 |
Cytokines/*metabolism | 2 | 0.0 |
Macrophages/*immunology | 2 | 0.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Radioimmunoassay | 10 | 0.0 |
*Cell Cycle Proteins | 7 | 0.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*immunology | 2 | 66.0 |
Severity of Illness Index | 4 | 0.0 |
Cell Survival/drug effects/radiation effects | 4 | 9.0 |
Gene Expression Regulation, Neoplastic/radiation effects | 2 | 15.0 |
*Gene Therapy | 3 | 0.0 |
Breast Neoplasms/pathology/*physiopathology | 2 | 25.0 |
Drug Resistance | 7 | 1.0 |
Estradiol/*analogs & derivatives/*pharmacology | 5 | 25.0 |
Estrogen Receptor Modulators/*pharmacology | 3 | 12.0 |
Mitogen-Activated Protein Kinases/physiology | 4 | 3.0 |
Neovascularization, Pathologic/*diagnosis | 2 | 13.0 |
Cisplatin/pharmacology | 4 | 2.0 |
Doxorubicin/pharmacology | 3 | 1.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/genetics | 6 | 60.0 |
Enzyme Activation/drug effects | 25 | 2.0 |
G1 Phase/drug effects | 3 | 2.0 |
Up-Regulation/drug effects | 7 | 1.0 |
Temperature | 8 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
*Neoplasm Circulating Cells | 3 | 7.0 |
*Reverse Transcriptase Polymerase Chain Reaction | 3 | 5.0 |
Receptors, Growth Factor/physiology | 2 | 4.0 |
Liposomes | 7 | 2.0 |
Receptor, Epidermal Growth Factor/chemistry/*metabolism | 8 | 22.0 |
Thermodynamics | 3 | 0.0 |
Ovarian Neoplasms/*metabolism/pathology | 5 | 7.0 |
Pancreatic Neoplasms/*drug therapy/metabolism | 2 | 50.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 24 | 2.0 |
Receptor, Epidermal Growth Factor/physiology | 15 | 19.0 |
Genes, erbB-1/drug effects | 2 | 100.0 |
Genes, erbB-2/drug effects | 2 | 100.0 |
Receptor, Epidermal Growth Factor/drug effects | 5 | 25.0 |
Catalysis | 5 | 0.0 |
Glutathione Transferase/metabolism | 9 | 1.0 |
Hydrogen-Ion Concentration | 12 | 0.0 |
Lysosomes/metabolism | 8 | 5.0 |
RNA, Small Interfering/metabolism | 7 | 3.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Ubiquitin/*metabolism | 6 | 3.0 |
Ubiquitin-Protein Ligases/metabolism | 3 | 6.0 |
src Homology Domains | 15 | 2.0 |
Oncogenes | 12 | 4.0 |
Cell Division/*drug effects/physiology | 2 | 10.0 |
Pilot Projects | 10 | 1.0 |
Glioma | 3 | 4.0 |
Indicators and Reagents | 4 | 1.0 |
Molecular Conformation | 5 | 2.0 |
Pyrimidines/*chemical synthesis/chemistry/pharmacology | 2 | 9.0 |
Recombinant Proteins/antagonists & inhibitors | 2 | 4.0 |
Epithelial Cells/cytology | 4 | 5.0 |
Mouth Neoplasms/metabolism/pathology | 2 | 50.0 |
Proliferating Cell Nuclear Antigen/*metabolism | 3 | 1.0 |
Hydrolysis | 6 | 0.0 |
Tumor Markers, Biological/metabolism | 16 | 4.0 |
Antibodies, Monoclonal/immunology | 14 | 0.0 |
Chickens | 8 | 1.0 |
Cross Reactions | 3 | 0.0 |
Drug Screening Assays, Antitumor/methods | 3 | 18.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Cervix Neoplasms/*metabolism/pathology | 6 | 33.0 |
*Trans-Activators | 4 | 0.0 |
Chloroquine/pharmacology | 2 | 2.0 |
Receptor, Epidermal Growth Factor/analysis/*metabolism | 10 | 50.0 |
Enzyme Inhibitors/isolation & purification/pharmacology | 2 | 28.0 |
Jurkat Cells | 4 | 0.0 |
Decidua/*metabolism | 2 | 5.0 |
Endometrium/*metabolism | 3 | 3.0 |
RNA, Messenger/biosynthesis/genetics | 14 | 2.0 |
Trophoblasts/*metabolism | 3 | 6.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/antagonists & inhibitors | 3 | 13.0 |
Extracellular Matrix/*physiology | 4 | 9.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 13 | 7.0 |
Oligopeptides/pharmacology | 3 | 1.0 |
Protein-Tyrosine-Phosphatase/antagonists & inhibitors | 5 | 14.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*metabolism | 3 | 4.0 |
Androstadienes/pharmacology | 6 | 2.0 |
Endothelial Growth Factors/*genetics | 2 | 1.0 |
Insulin-Like Growth Factor I/*pharmacology | 3 | 2.0 |
Lymphokines/*genetics | 2 | 0.0 |
Recombinant Proteins/pharmacology | 15 | 0.0 |
Life Tables | 7 | 4.0 |
Neoplasm Proteins/analysis/*genetics | 2 | 6.0 |
Carcinoma, Squamous Cell/*drug therapy | 8 | 29.0 |
Head and Neck Neoplasms/*drug therapy | 6 | 35.0 |
Chloride Channels/*metabolism | 2 | 15.0 |
Colon/cytology | 2 | 13.0 |
Cytosol/enzymology | 2 | 1.0 |
Enzyme Activation/physiology | 6 | 3.0 |
Transforming Growth Factor alpha/*pharmacology | 10 | 17.0 |
Genes, erbB-2/physiology | 3 | 42.0 |
Chromatography, Affinity | 3 | 0.0 |
Phosphatidylinositol Phosphates/*metabolism | 2 | 6.0 |
Phosphoric Monoester Hydrolases/*biosynthesis | 2 | 16.0 |
Variation (Genetics) | 7 | 0.0 |
Cytoskeletal Proteins/*metabolism | 6 | 3.0 |
Molecular Weight | 23 | 0.0 |
Receptors, Growth Factor/biosynthesis | 3 | 10.0 |
Brain Neoplasms/*pathology | 8 | 10.0 |
Cell Nucleus/*pathology | 2 | 16.0 |
Densitometry | 2 | 1.0 |
Fourier Analysis | 2 | 3.0 |
Ki-67 Antigen/*analysis | 4 | 5.0 |
Breast Neoplasms/*metabolism/mortality | 3 | 50.0 |
Phorbol 12,13-Dibutyrate/pharmacology | 2 | 3.0 |
Platelet-Derived Growth Factor/pharmacology | 6 | 3.0 |
Receptor, erbB-2/immunology/*metabolism | 3 | 33.0 |
Vanadates/pharmacology | 8 | 5.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Keratinocytes/*metabolism | 4 | 4.0 |
Mitogen-Activated Protein Kinases/drug effects/metabolism | 4 | 9.0 |
Protein-Tyrosine Kinase/drug effects/metabolism | 2 | 15.0 |
Radiotherapy, Adjuvant | 2 | 2.0 |
Receptor, erbB-2/*analysis/physiology | 2 | 100.0 |
Receptors, Estrogen/*biosynthesis | 2 | 8.0 |
Receptors, Progesterone/biosynthesis | 3 | 9.0 |
DNA, Viral/genetics | 2 | 1.0 |
Gene Expression Regulation, Viral | 3 | 1.0 |
Receptor, Epidermal Growth Factor/biosynthesis/genetics/*physiology | 5 | 62.0 |
Astrocytoma/*genetics/metabolism/pathology | 2 | 16.0 |
Gene Dosage | 9 | 2.0 |
Glial Fibrillary Acidic Protein/genetics | 2 | 7.0 |
Mice, Inbred ICR | 5 | 2.0 |
*Genes, erbB | 3 | 27.0 |
Carcinoma, Squamous Cell/pathology | 7 | 15.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Cyclin D1/analysis | 3 | 7.0 |
Mouth Neoplasms/pathology | 2 | 40.0 |
*Diet | 2 | 0.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Animals, Genetically Modified | 2 | 0.0 |
Genes, Helminth | 2 | 8.0 |
RNA Interference | 5 | 1.0 |
Transcription Factors/genetics/physiology | 2 | 3.0 |
S100 Proteins/metabolism | 3 | 2.0 |
Camptothecin/*analogs & derivatives/therapeutic use | 2 | 28.0 |
Vascular Endothelial Growth Factor A/*antagonists & inhibitors | 2 | 15.0 |
HLA-DR Antigens/analysis | 3 | 0.0 |
Poland | 2 | 1.0 |
S100 Proteins/analysis | 3 | 1.0 |
Tenascin/analysis | 2 | 33.0 |
Transforming Growth Factor beta/analysis | 2 | 4.0 |
von Willebrand Factor/analysis | 2 | 0.0 |
Chronic Disease | 5 | 0.0 |
Phosphoric Monoester Hydrolases/*metabolism | 2 | 2.0 |
Proto-Oncogene Proteins/*metabolism | 28 | 2.0 |
Tumor Suppressor Proteins/*metabolism | 3 | 3.0 |
Androgens/pharmacology | 4 | 8.0 |
Receptors, Androgen/genetics/*metabolism | 2 | 4.0 |
Autocrine Communication | 3 | 4.0 |
Biotinylation | 2 | 1.0 |
Cell Culture Techniques | 7 | 1.0 |
Indoles/pharmacology | 3 | 1.0 |
Maleimides/pharmacology | 3 | 3.0 |
Serine/chemistry | 2 | 1.0 |
Threonine/chemistry | 2 | 2.0 |
Transforming Growth Factor alpha/metabolism/*physiology | 2 | 100.0 |
Cell Differentiation/physiology | 6 | 1.0 |
Epidermis/cytology | 2 | 5.0 |
Keratinocytes/cytology/*metabolism | 2 | 5.0 |
Mitogen-Activated Protein Kinase 11 | 2 | 25.0 |
Autocrine Communication/genetics | 2 | 40.0 |
Cell Movement/genetics | 3 | 8.0 |
Gene Expression Regulation, Neoplastic/genetics | 7 | 3.0 |
Neoplasm Invasiveness/*genetics | 3 | 8.0 |
Phospholipase C/antagonists & inhibitors/metabolism | 2 | 12.0 |
Prostatic Neoplasms/genetics/*metabolism | 2 | 7.0 |
Signal Transduction/drug effects/genetics | 4 | 11.0 |
Up-Regulation/genetics | 2 | 2.0 |
DNA Replication/drug effects | 5 | 2.0 |
Plaque Assay | 2 | 2.0 |
*Genes, Tumor Suppressor | 11 | 1.0 |
Mammary Neoplasms, Animal/metabolism | 2 | 22.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 2 | 2.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Piperidines/*pharmacology | 5 | 9.0 |
Cell Count | 9 | 0.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/physiology | 5 | 62.0 |
Transforming Growth Factor alpha/*biosynthesis/genetics | 5 | 31.0 |
Oxidation-Reduction | 4 | 0.0 |
Proto-Oncogene Protein pp60(c-src)/metabolism | 2 | 5.0 |
Receptor, Angiotensin, Type 1 | 2 | 1.0 |
G2 Phase/drug effects | 2 | 4.0 |
Pyridines/*pharmacology | 2 | 3.0 |
*Sequence Deletion | 3 | 0.0 |
*Radiation Tolerance | 7 | 12.0 |
Blotting, Southern | 44 | 1.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Breast Neoplasms/genetics/metabolism/*pathology | 6 | 17.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Gene Expression Regulation/*physiology | 5 | 1.0 |
Hyperplasia | 12 | 3.0 |
Precancerous Conditions/metabolism/pathology | 3 | 20.0 |
Skin Neoplasms/metabolism/*pathology | 2 | 5.0 |
Papillomavirus, Human/*isolation & purification | 3 | 11.0 |
Proto-Oncogene Protein c-met/metabolism | 4 | 5.0 |
Stomach Neoplasms/*pathology | 6 | 12.0 |
Cell Differentiation/drug effects/*physiology | 2 | 3.0 |
Cell Division/*physiology | 5 | 2.0 |
RNA, Messenger/analysis/genetics | 5 | 1.0 |
Receptor, Epidermal Growth Factor/analysis/*genetics/physiology | 2 | 100.0 |
*Transcription, Genetic | 11 | 0.0 |
Lung Neoplasms | 7 | 6.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 10 | 3.0 |
Protein Kinases/metabolism | 6 | 1.0 |
Epidermal Growth Factor/*immunology | 2 | 25.0 |
DNA, Neoplasm/metabolism | 9 | 6.0 |
Tumor Markers, Biological/genetics/*metabolism | 4 | 10.0 |
Membrane Proteins/metabolism | 7 | 1.0 |
Microinjections | 2 | 0.0 |
*Vesicular Transport Proteins | 5 | 2.0 |
Apoptosis/*physiology | 8 | 1.0 |
Epithelium/*pathology | 2 | 50.0 |
Breast Neoplasms/genetics/*metabolism | 6 | 10.0 |
Cytokines/metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 6 | 4.0 |
Receptor, Platelet-Derived Growth Factor beta/metabolism | 2 | 16.0 |
Trans-Activation (Genetics)/genetics | 2 | 2.0 |
src-Family Kinases/metabolism | 8 | 4.0 |
Bladder Neoplasms/*pathology | 3 | 13.0 |
Adenocarcinoma/genetics/*pathology | 2 | 9.0 |
Cadherins/*biosynthesis | 3 | 9.0 |
*Immunohistochemistry | 3 | 3.0 |
Antibodies/pharmacology | 4 | 1.0 |
RNA, Small Interfering | 5 | 9.0 |
Antigens, CD40/metabolism | 2 | 3.0 |
Dinoprostone/metabolism | 2 | 2.0 |
Isoenzymes/metabolism | 19 | 3.0 |
Phosphoproteins/metabolism | 8 | 1.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 6 | 8.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology | 3 | 100.0 |
Lung Neoplasms/*drug therapy/metabolism/pathology | 3 | 37.0 |
Receptor, Epidermal Growth Factor/immunology | 6 | 31.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 2 | 1.0 |
Peptide Hydrolases/metabolism | 3 | 2.0 |
Proto-Oncogene Proteins/genetics/metabolism | 4 | 2.0 |
Brain Neoplasms/*genetics/*metabolism/pathology | 2 | 50.0 |
Glioblastoma/*genetics/*metabolism/pathology | 2 | 100.0 |
Carcinoma, Squamous Cell/immunology/metabolism/*therapy | 2 | 100.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*immunology | 2 | 66.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 7 | 0.0 |
Neoplasms/*therapy | 5 | 4.0 |
*Peptide Library | 2 | 3.0 |
Antibodies, Monoclonal/*therapeutic use/toxicity | 2 | 40.0 |
Breast/chemistry | 2 | 9.0 |
Carcinoma, Ductal, Breast/chemistry | 2 | 25.0 |
Carcinoma, Lobular/chemistry | 2 | 66.0 |
Proto-Oncogene Proteins/analysis | 7 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 5 | 5.0 |
Retinoblastoma Protein/analysis | 7 | 20.0 |
Apoptosis/*genetics | 2 | 0.0 |
*DNA Repair | 2 | 0.0 |
Radiation Tolerance/*genetics | 2 | 3.0 |
Radiation-Sensitizing Agents/pharmacology | 2 | 8.0 |
Adenocarcinoma/pathology | 7 | 8.0 |
Genes, erbB-2/genetics | 2 | 7.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Receptors, Vascular Endothelial Growth Factor | 3 | 0.0 |
Escherichia coli/metabolism | 4 | 1.0 |
Peptide Mapping | 6 | 1.0 |
Receptor, Epidermal Growth Factor/*chemistry/metabolism | 3 | 30.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
Threonine/metabolism | 4 | 4.0 |
Gene Expression Regulation/drug effects/physiology | 2 | 3.0 |
Growth Substances/genetics | 5 | 7.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Rats, Wistar | 4 | 0.0 |
Transforming Growth Factor alpha/genetics | 7 | 26.0 |
*JNK Mitogen-Activated Protein Kinases | 4 | 4.0 |
*DNA Damage | 5 | 0.0 |
Dacarbazine/*analogs & derivatives/pharmacology | 2 | 18.0 |
Quinazolines/chemical synthesis/chemistry/*pharmacology | 2 | 100.0 |
Gene Expression/physiology | 4 | 1.0 |
Goblet Cells/*pathology | 2 | 40.0 |
Mucins/genetics | 2 | 10.0 |
RNA, Messenger/*genetics | 8 | 2.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Antibodies/diagnostic use | 4 | 9.0 |
Antibody Specificity/immunology | 2 | 3.0 |
Astrocytes/metabolism/pathology | 2 | 7.0 |
Receptor, Epidermal Growth Factor/analysis/*biosynthesis/genetics | 2 | 100.0 |
Antineoplastic Agents/pharmacokinetics/*therapeutic use | 2 | 50.0 |
Cell Line, Tumor/drug effects | 2 | 8.0 |
Quinazolines/pharmacokinetics/*therapeutic use | 2 | 66.0 |
Carcinoma, Squamous Cell/drug therapy/metabolism | 5 | 55.0 |
Lung Neoplasms/*drug therapy/metabolism | 4 | 25.0 |
Neoplasms, Hormone-Dependent/metabolism | 2 | 28.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 4 | 4.0 |
Mouth Mucosa/metabolism | 2 | 11.0 |
Skin/metabolism | 3 | 1.0 |
Antibodies, Blocking/pharmacology | 4 | 4.0 |
Cell Membrane/drug effects/metabolism | 2 | 2.0 |
Cell Movement/drug effects | 6 | 1.0 |
Interstitial Collagenase/metabolism | 2 | 8.0 |
Keratinocytes/*drug effects | 2 | 11.0 |
Protein Transport/physiology | 5 | 4.0 |
Protein-Serine-Threonine Kinases/physiology | 4 | 4.0 |
Proto-Oncogene Proteins/physiology | 4 | 3.0 |
Cell Division/drug effects/radiation effects | 4 | 16.0 |
Endothelial Growth Factors/metabolism | 5 | 2.0 |
Head and Neck Neoplasms/*radiotherapy | 2 | 25.0 |
Lymphokines/metabolism | 5 | 2.0 |
Neoplasm Proteins/*antagonists & inhibitors/metabolism | 4 | 44.0 |
DNA-Binding Proteins/genetics/metabolism | 3 | 0.0 |
*Embryonic Induction | 2 | 9.0 |
Genes, Reporter | 12 | 0.0 |
Insect Proteins/genetics/*metabolism | 2 | 20.0 |
Membrane Proteins/genetics/metabolism | 2 | 1.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Cell Nucleus/metabolism | 19 | 1.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Introns | 9 | 0.0 |
Models, Genetic | 8 | 0.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/*genetics | 3 | 60.0 |
Biopsy/methods | 2 | 4.0 |
Lung Neoplasms/*physiopathology | 2 | 20.0 |
*Alternative Splicing | 3 | 0.0 |
Chromosomes, Human, Pair 7 | 11 | 7.0 |
Evolution, Molecular | 5 | 0.0 |
Exons | 8 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Mitogen-Activated Protein Kinases/genetics/*metabolism | 2 | 4.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 3 | 3.0 |
src-Family Kinases/antagonists & inhibitors/metabolism | 2 | 15.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Adenocarcinoma/drug therapy/pathology | 3 | 60.0 |
Mitosis/drug effects | 2 | 1.0 |
Multidrug Resistance-Associated Proteins | 3 | 4.0 |
Proto-Oncogene Proteins/biosynthesis | 4 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 3 | 2.0 |
Antineoplastic Agents, Phytogenic/therapeutic use | 2 | 14.0 |
Body Weight/drug effects | 2 | 1.0 |
Lung Neoplasms/drug therapy | 5 | 21.0 |
Maximum Tolerated Dose | 4 | 10.0 |
Prostatic Neoplasms/drug therapy | 2 | 22.0 |
Menopause | 11 | 5.0 |
Epidermal Growth Factor/genetics/metabolism | 7 | 50.0 |
Intestinal Mucosa/*metabolism | 3 | 3.0 |
RNA, Messenger/*metabolism | 9 | 1.0 |
Antibodies, Bispecific/*therapeutic use | 2 | 20.0 |
*Immunotherapy, Adoptive | 2 | 3.0 |
*Lymphocyte Activation | 2 | 0.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Central Nervous System Neoplasms/*genetics | 3 | 21.0 |
Gene Amplification/*genetics | 14 | 13.0 |
Endometrial Neoplasms/*metabolism | 3 | 9.0 |
Receptors, Cell Surface/*metabolism | 12 | 2.0 |
Gene Expression/drug effects | 8 | 1.0 |
Models, Statistical | 2 | 1.0 |
Extracellular Matrix/physiology | 2 | 2.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
*Receptor Protein-Tyrosine Kinases | 2 | 3.0 |
Receptor, Epidermal Growth Factor/analysis/genetics | 5 | 71.0 |
Neoplasms/*drug therapy/physiopathology | 3 | 37.0 |
Signal Transduction/*drug effects/physiology | 5 | 8.0 |
Adenocarcinoma/*metabolism/secondary | 2 | 25.0 |
Colorectal Neoplasms/*metabolism/pathology | 4 | 8.0 |
Neoplasm Invasiveness/physiopathology | 3 | 17.0 |
Proto-Oncogene Protein c-met/*metabolism | 6 | 10.0 |
Actins/metabolism | 4 | 0.0 |
Cytochalasin B/analogs & derivatives/pharmacology | 2 | 66.0 |
Frameshift Mutation | 4 | 1.0 |
Protein p16/genetics/metabolism | 2 | 7.0 |
Cell Death/*drug effects | 2 | 6.0 |
Hepatocyte Growth Factor/pharmacology | 2 | 3.0 |
Pancreatic Neoplasms | 3 | 7.0 |
Carcinoma in Situ/genetics/metabolism/pathology | 2 | 25.0 |
Colorimetry | 2 | 3.0 |
RNA, Neoplasm/biosynthesis/genetics | 2 | 3.0 |
Receptors, Growth Factor/biosynthesis/genetics | 2 | 16.0 |
Astrocytoma/*metabolism/pathology | 3 | 13.0 |
Brain Neoplasms/*metabolism/pathology | 8 | 17.0 |
Biological Transport | 10 | 0.0 |
Extracellular Matrix Proteins/analysis | 4 | 22.0 |
Cyclic AMP-Dependent Protein Kinases/*antagonists & inhibitors | 2 | 40.0 |
Oligonucleotides, Antisense/*therapeutic use | 2 | 14.0 |
Drug Delivery Systems/*methods | 6 | 15.0 |
Drug Resistance, Neoplasm/*physiology | 3 | 9.0 |
Pyrimidines/therapeutic use | 2 | 9.0 |
Cercopithecus aethiops | 7 | 0.0 |
Cell Cycle Proteins/metabolism | 2 | 0.0 |
Tumor Suppressor Proteins/metabolism | 4 | 3.0 |
Calcium/metabolism | 19 | 1.0 |
Proto-Oncogene Proteins c-fos/metabolism | 4 | 3.0 |
Neoplasm Metastasis/*physiopathology | 2 | 6.0 |
Endometrium/*pathology | 2 | 10.0 |
*Postmenopause | 2 | 3.0 |
Adaptor Proteins, Vesicular Transport | 2 | 2.0 |
Disintegrins/metabolism | 2 | 22.0 |
Membrane Proteins/*metabolism | 4 | 0.0 |
Pseudomonas aeruginosa/*physiology | 2 | 40.0 |
Carrier Proteins/metabolism | 6 | 0.0 |
Recombinant Fusion Proteins | 10 | 3.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 3 | 2.0 |
Keratinocytes/*physiology | 5 | 14.0 |
Mitogen-Activated Protein Kinase Kinases/*physiology | 2 | 20.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 3 | 2.0 |
Administration, Intravesical | 2 | 7.0 |
Drug Carriers | 3 | 2.0 |
*Antiretroviral Therapy, Highly Active | 2 | 0.0 |
Developing Countries | 2 | 2.0 |
Tuberculosis/epidemiology/*prevention & control | 2 | 20.0 |
Antibodies/immunology | 2 | 0.0 |
Glycosylation | 6 | 0.0 |
Receptor, Epidermal Growth Factor/*chemistry/genetics/*metabolism | 4 | 50.0 |
Tunicamycin/pharmacology | 3 | 3.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Postoperative Period | 2 | 0.0 |
Keratin/analysis | 4 | 1.0 |
Vimentin/analysis | 2 | 0.0 |
Cell Membrane Permeability | 3 | 1.0 |
Epidermal Growth Factor/metabolism/*pharmacology | 6 | 8.0 |
Inositol Phosphates/metabolism | 2 | 1.0 |
Phospholipase C/metabolism | 17 | 5.0 |
Protein Binding/drug effects | 5 | 1.0 |
Biological Transport/drug effects | 3 | 1.0 |
Endocytosis/*drug effects | 3 | 13.0 |
Fibroblasts | 9 | 1.0 |
Antigens, CD44/*analysis | 2 | 1.0 |
Antigens, Neoplasm/*analysis | 8 | 2.0 |
Breast Neoplasms/*immunology | 2 | 3.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Glutamic Acid/metabolism | 2 | 4.0 |
Phorbol Esters/pharmacology | 3 | 2.0 |
Cell Cycle Proteins/biosynthesis | 4 | 15.0 |
Chromosome Aberrations | 10 | 1.0 |
*Oncogenes | 18 | 4.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 4 | 2.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/metabolism | 2 | 20.0 |
Stromal Cells/chemistry | 2 | 8.0 |
*RNA, Antisense | 3 | 33.0 |
*Cell Movement/drug effects | 3 | 25.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
Neutrophils/cytology | 2 | 4.0 |
Receptors, Estrogen/biosynthesis | 2 | 4.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 5 | 1.0 |
Macaca mulatta | 2 | 0.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/immunology | 3 | 50.0 |
Thionucleotides/*pharmacology | 2 | 11.0 |
Transforming Growth Factor alpha/biosynthesis | 5 | 35.0 |
Solubility | 8 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 4 | 1.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Growth Substances/biosynthesis | 2 | 10.0 |
*Mucins | 2 | 2.0 |
*Neuropeptides | 2 | 1.0 |
Peptides | 2 | 3.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Genistein/pharmacology | 5 | 4.0 |
Binding Sites/genetics | 7 | 0.0 |
Phosphoproteins/genetics/*metabolism | 4 | 2.0 |
Recombinant Fusion Proteins/biosynthesis | 5 | 1.0 |
Tyrosine/genetics/*metabolism | 2 | 8.0 |
Fluorescence Polarization | 2 | 3.0 |
Bladder Neoplasms/*metabolism | 3 | 17.0 |
Carcinoma, Transitional Cell/*metabolism | 2 | 25.0 |
Mouth Neoplasms/*metabolism | 3 | 12.0 |
Pyrimidines/chemistry/*pharmacology | 3 | 75.0 |
Adenocarcinoma/*pathology | 6 | 7.0 |
Proto-Oncogene Protein pp60(c-src)/*metabolism | 4 | 10.0 |
Tenascin/*metabolism | 2 | 18.0 |
Bladder Neoplasms/*metabolism/mortality/pathology | 2 | 33.0 |
CA-15-3 Antigen/*metabolism | 2 | 3.0 |
Carcinoma, Squamous Cell/*metabolism/mortality/pathology | 2 | 28.0 |
Mucins/*metabolism | 4 | 4.0 |
Adenocarcinoma/genetics/*metabolism | 4 | 23.0 |
Carcinoma, Large Cell/genetics/metabolism | 2 | 66.0 |
Carcinoma, Non-Small-Cell Lung/genetics/*metabolism | 2 | 33.0 |
Carcinoma, Squamous Cell/genetics/metabolism | 4 | 22.0 |
Lung Neoplasms/genetics/*metabolism | 2 | 11.0 |
Transforming Growth Factor alpha/genetics/*metabolism | 7 | 46.0 |
*Gene Expression Regulation | 9 | 0.0 |
Genes, erbB | 2 | 25.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism/*physiology | 2 | 33.0 |
Intestinal Mucosa/metabolism | 2 | 1.0 |
Carcinoma, Papillary/*metabolism | 2 | 16.0 |
Protein Precursors/*metabolism | 2 | 2.0 |
Growth Substances/metabolism | 13 | 10.0 |
Cattle | 9 | 0.0 |
*Gene Expression/drug effects | 2 | 6.0 |
Keratinocytes/cytology/metabolism | 2 | 7.0 |
Oncogene Proteins, Viral/genetics/*metabolism | 2 | 6.0 |
Lung/drug effects/*metabolism | 2 | 20.0 |
Mitogen-Activated Protein Kinase Kinases/*metabolism | 2 | 3.0 |
*Smoking | 2 | 2.0 |
Transcription Factors/metabolism | 6 | 0.0 |
Pyrimidines/*therapeutic use | 2 | 4.0 |
Receptor, Epidermal Growth Factor/analysis/biosynthesis | 3 | 60.0 |
Mice, Inbred CBA | 3 | 0.0 |
Skin Neoplasms/*metabolism | 2 | 5.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Nitriles/pharmacology | 6 | 5.0 |
Chromosomes, Human, Pair 1/genetics | 4 | 2.0 |
Chromosomes, Human, Pair 19/genetics | 4 | 3.0 |
Genes, myc/genetics | 6 | 7.0 |
Chimeric Proteins/metabolism | 4 | 2.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 2 | 3.0 |
Receptors, Antigen, T-Cell/metabolism | 4 | 2.0 |
Keratinocytes/chemistry/pathology | 2 | 50.0 |
Keratosis/pathology | 2 | 33.0 |
*Proto-Oncogene Proteins c-bcl-2 | 4 | 0.0 |
Calcium Signaling/drug effects/*physiology | 2 | 11.0 |
Transforming Growth Factor beta/antagonists & inhibitors | 2 | 12.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 19 | 5.0 |
Protein-Serine-Threonine Kinases/*chemistry | 2 | 15.0 |
Serine/metabolism | 2 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Aorta | 2 | 1.0 |
Papio | 3 | 1.0 |
Neoplasm Recurrence, Local/epidemiology | 4 | 21.0 |
Breast/*physiology | 2 | 20.0 |
Receptor, erbB-2/*genetics | 5 | 13.0 |
Transforming Growth Factor alpha/genetics/*physiology | 4 | 100.0 |
Culture Media | 7 | 1.0 |
Receptor, Epidermal Growth Factor/biosynthesis/metabolism | 4 | 66.0 |
Wound Healing/physiology | 3 | 5.0 |
Gelatinase B/*biosynthesis | 2 | 14.0 |
Actins/genetics | 7 | 5.0 |
*Biological Markers | 2 | 1.0 |
Chimeric Proteins/therapeutic use | 4 | 33.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Subcellular Fractions/metabolism | 6 | 1.0 |
Kidney Neoplasms/*drug therapy/pathology | 2 | 50.0 |
Tumor Cells, Cultured/drug effects/pathology | 2 | 4.0 |
*Cell Differentiation | 2 | 0.0 |
Cell Proliferation | 5 | 2.0 |
Antibody Formation | 3 | 0.0 |
Immunoglobulin G/metabolism | 2 | 1.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Lung Neoplasms/*immunology | 2 | 4.0 |
Peptides/*analysis | 2 | 2.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 3 | 4.0 |
Epidermal Growth Factor/*biosynthesis/genetics | 4 | 25.0 |
Liver Neoplasms/*metabolism/pathology | 3 | 4.0 |
Receptor, Epidermal Growth Factor/*drug effects/*metabolism | 2 | 50.0 |
Colon | 2 | 7.0 |
Neurotensin/*pharmacology | 2 | 33.0 |
Receptor, Epidermal Growth Factor/drug effects/metabolism | 7 | 16.0 |
Antibodies, Monoclonal/diagnostic use | 17 | 2.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Astrocytes/chemistry/physiology | 2 | 100.0 |
Endopeptidases/physiology | 2 | 13.0 |
Gene Expression Regulation, Neoplastic/*genetics | 15 | 7.0 |
Neoplasm Invasiveness/genetics | 2 | 4.0 |
Neovascularization, Pathologic/genetics | 3 | 9.0 |
Receptor, erbB-2/*physiology | 8 | 32.0 |
Signal Transduction/*genetics | 4 | 3.0 |
Carcinoma/*chemistry/*pathology | 2 | 50.0 |
Neoplasm Proteins/analysis | 18 | 5.0 |
Receptors, Progesterone/*analysis | 12 | 5.0 |
Apoptosis/drug effects/radiation effects | 4 | 25.0 |
Carcinoma, Squamous Cell/*drug therapy/pathology/*radiotherapy | 3 | 60.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Diarrhea/chemically induced | 2 | 8.0 |
Choriocarcinoma/genetics/*metabolism/pathology | 2 | 66.0 |
Cell Survival/*drug effects | 3 | 3.0 |
Protein p53/*biosynthesis | 2 | 1.0 |
Carcinoma, Squamous Cell/*pathology | 8 | 9.0 |
Tumor Cells, Cultured/*pathology | 2 | 10.0 |
Pregnancy/*metabolism | 2 | 3.0 |
Cell Movement/drug effects/*physiology | 5 | 10.0 |
Integrins/*metabolism | 4 | 2.0 |
Mutagenesis/physiology | 2 | 2.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
Deoxyribonuclease I | 4 | 2.0 |
*Promoter Regions (Genetics) | 14 | 0.0 |
Receptor, Epidermal Growth Factor/*chemistry/genetics/metabolism | 2 | 40.0 |
Hydrogen Peroxide/pharmacology | 4 | 1.0 |
*Oxidative Stress | 2 | 0.0 |
Retroviridae Proteins, Oncogenic/*metabolism | 3 | 10.0 |
Glycoproteins/physiology | 2 | 6.0 |
Ovarian Neoplasms/metabolism/*pathology | 2 | 12.0 |
Prostaglandin-Endoperoxide Synthase/genetics/*metabolism | 3 | 13.0 |
Risk Assessment | 11 | 1.0 |
*Genetic Markers | 4 | 1.0 |
Neoplasms/drug therapy/physiopathology | 3 | 60.0 |
Dynamins | 3 | 7.0 |
Angiotensin II/*pharmacology | 2 | 1.0 |
Cell Count/drug effects | 3 | 4.0 |
Genes, Tumor Suppressor/genetics | 3 | 1.0 |
Receptor, Epidermal Growth Factor/*drug effects/genetics/immunology | 2 | 100.0 |
Breast Neoplasms/genetics/pathology | 3 | 8.0 |
Neoplasms/*genetics/pathology | 2 | 5.0 |
Chlorides/metabolism | 3 | 3.0 |
Colon/metabolism | 4 | 3.0 |
Neutralization Tests | 4 | 0.0 |
Protein Precursors/metabolism | 3 | 2.0 |
Protein Processing, Post-Translational | 7 | 0.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/metabolism | 5 | 50.0 |
Transfection/methods | 2 | 1.0 |
DNA, Neoplasm/analysis/genetics | 8 | 9.0 |
Diploidy | 4 | 3.0 |
Cyclic AMP/metabolism | 4 | 0.0 |
Fibroblasts/cytology/metabolism | 3 | 1.0 |
Carrier Proteins/genetics | 3 | 0.0 |
Chromosomes, Human, Pair 10/genetics | 5 | 6.0 |
Chromosomes, Human, Pair 9/genetics | 3 | 2.0 |
Genes, Tumor Suppressor/*genetics | 8 | 2.0 |
Glioblastoma/*genetics/metabolism/pathology | 2 | 28.0 |
Protein p16 | 6 | 4.0 |
Protein p53/*genetics/metabolism | 3 | 7.0 |
Apoptosis/*drug effects/genetics | 3 | 9.0 |
DNA, Antisense/genetics | 4 | 8.0 |
Recombinant Fusion Proteins/physiology | 3 | 1.0 |
Tumor Markers, Biological/analysis/*genetics | 3 | 14.0 |
Placebos | 2 | 0.0 |
Apoptosis/*radiation effects | 2 | 4.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 3 | 3.0 |
*Mitosis | 2 | 1.0 |
Prostatic Neoplasms/*enzymology/metabolism/pathology | 3 | 50.0 |
Head and Neck Neoplasms/*genetics/*pathology | 3 | 100.0 |
Receptor, Epidermal Growth Factor/analysis/*immunology | 2 | 50.0 |
Electrophoresis | 2 | 0.0 |
DNA Replication/physiology | 3 | 9.0 |
Neuregulin-1/*physiology | 2 | 22.0 |
Ovarian Neoplasms/*metabolism | 3 | 5.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Tetracycline/*pharmacology | 2 | 11.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Liver Neoplasms | 3 | 1.0 |
*Receptor Cross-Talk | 4 | 28.0 |
Glial Fibrillary Acidic Protein/analysis | 2 | 1.0 |
Glioblastoma/pathology | 2 | 11.0 |
Neovascularization, Pathologic/pathology | 3 | 5.0 |
Antineoplastic Agents, Alkylating/*pharmacology | 2 | 5.0 |
Carmustine/pharmacology | 2 | 9.0 |
DNA Primers/genetics | 6 | 0.0 |
Transforming Growth Factor alpha/*genetics/*metabolism | 4 | 100.0 |
Cathepsin D/metabolism | 4 | 10.0 |
*Introns | 4 | 1.0 |
Laryngeal Neoplasms/genetics/pathology | 2 | 50.0 |
Larynx/*pathology | 2 | 50.0 |
Protein p53/*genetics | 7 | 4.0 |
Cell Lineage | 2 | 0.0 |
Chemotaxis | 2 | 1.0 |
Transcription Factors/physiology | 2 | 0.0 |
Breast Neoplasms/blood supply/*metabolism/pathology | 2 | 15.0 |
Brain Neoplasms/pathology | 2 | 10.0 |
Exons/genetics | 5 | 0.0 |
PC12 Cells | 5 | 1.0 |
Transcription, Genetic/*drug effects | 5 | 1.0 |
G1 Phase/*drug effects | 2 | 2.0 |
Retinoblastoma Protein/metabolism | 6 | 1.0 |
Necrosis | 3 | 0.0 |
Head and Neck Neoplasms/metabolism | 2 | 28.0 |
Receptor, Epidermal Growth Factor/*immunology/*metabolism | 2 | 100.0 |
Alternative Splicing | 9 | 0.0 |
*Mitotic Index | 2 | 20.0 |
Astrocytes/pathology | 2 | 5.0 |
Brain/pathology | 5 | 1.0 |
Carrier Proteins/*genetics | 5 | 0.0 |
Neuroglia/pathology | 2 | 9.0 |
Neovascularization, Pathologic/prevention & control | 2 | 6.0 |
Liver/drug effects/pathology | 2 | 10.0 |
Receptor, Epidermal Growth Factor/*drug effects/metabolism | 7 | 23.0 |
Cell Compartmentation | 5 | 1.0 |
Microscopy, Immunoelectron | 8 | 1.0 |
Ovarian Neoplasms/*metabolism/mortality/pathology | 2 | 20.0 |
Biological Transport, Active | 3 | 1.0 |
Phosphoproteins/chemistry/genetics/*metabolism | 2 | 4.0 |
Phosphoric Monoester Hydrolases/metabolism | 4 | 5.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*pathology | 4 | 16.0 |
Lung Neoplasms/*pathology | 5 | 7.0 |
Deoxycytidine/administration & dosage/*analogs & derivatives | 4 | 20.0 |
Pancreatic Neoplasms/*drug therapy/pathology | 2 | 20.0 |
Phospholipases A/metabolism | 2 | 3.0 |
Protein p16/*genetics | 2 | 2.0 |
Enzyme Activation/drug effects/radiation effects | 2 | 22.0 |
Hydrogen Peroxide/metabolism/*pharmacology | 2 | 50.0 |
Enzyme Inhibitors/chemistry/*pharmacology | 3 | 10.0 |
Spectrum Analysis, Mass | 5 | 0.0 |
Prostatic Neoplasms/*chemistry | 2 | 14.0 |
Estrogen Antagonists/*pharmacology | 6 | 8.0 |
Cell Separation | 2 | 0.0 |
Paracrine Communication/physiology | 2 | 8.0 |
Stromal Cells/*physiology | 2 | 8.0 |
Head and Neck Neoplasms/metabolism/pathology | 3 | 27.0 |
Brain Neoplasms/*genetics/mortality | 4 | 80.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Proteins/*genetics/metabolism | 3 | 1.0 |
Syndrome | 7 | 0.0 |
Fluorouracil/pharmacology | 2 | 3.0 |
Glioblastoma/*pathology | 7 | 25.0 |
Proto-Oncogene Proteins/*biosynthesis | 3 | 1.0 |
Carcinoma, Squamous Cell/drug therapy | 3 | 23.0 |
Disulfides/metabolism | 3 | 8.0 |
GTP-Binding Proteins/metabolism | 4 | 1.0 |
Enzyme Inhibitors/adverse effects/*therapeutic use | 2 | 25.0 |
Receptors, Progesterone/*biosynthesis | 2 | 12.0 |
Oncogene Proteins/*metabolism | 3 | 3.0 |
*Ampulla of Vater | 2 | 18.0 |
Pancreatic Neoplasms/*metabolism | 4 | 5.0 |
Blotting, Western/methods | 4 | 2.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Receptors, Retinoic Acid/genetics/*physiology | 2 | 25.0 |
Retinoids/*pharmacology | 3 | 5.0 |
Heat | 2 | 0.0 |
Killer Cells, Lymphokine-Activated/*immunology | 2 | 2.0 |
Intermediate Filament Proteins/biosynthesis | 2 | 25.0 |
Protein Kinase C/physiology | 2 | 1.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
Folic Acid/*pharmacology | 2 | 22.0 |
Gastrointestinal Neoplasms/*metabolism | 2 | 15.0 |
Astrocytoma/genetics/pathology | 3 | 30.0 |
Bromodeoxyuridine/metabolism | 4 | 5.0 |
Thrombin/*pharmacology | 2 | 1.0 |
Glycoproteins/*physiology | 2 | 3.0 |
Growth Substances/*physiology | 4 | 2.0 |
*Genes, Suppressor | 2 | 8.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
*Zinc Fingers | 2 | 0.0 |
Glycoproteins/metabolism | 13 | 7.0 |
Ribonucleases/metabolism | 3 | 2.0 |
Bacteriophages/*genetics | 2 | 18.0 |
Gastric Mucosa/metabolism | 2 | 4.0 |
Glycoproteins/genetics/*metabolism | 2 | 5.0 |
Precancerous Conditions/metabolism | 2 | 12.0 |
Stomach Neoplasms/*metabolism/pathology | 5 | 8.0 |
Membrane Potentials | 2 | 0.0 |
Stress, Mechanical | 4 | 1.0 |
Epithelial Cells/drug effects/*metabolism | 2 | 8.0 |
Contrast Media | 2 | 3.0 |
Radiation Dosage | 3 | 3.0 |
Cross-Linking Reagents | 4 | 1.0 |
Cell Membrane/chemistry | 6 | 4.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology | 9 | 45.0 |
Antineoplastic Agents/administration & dosage/therapeutic use | 2 | 25.0 |
Quinazolines/administration & dosage/therapeutic use | 2 | 100.0 |
Receptor, Epidermal Growth Factor/*drug effects/*physiology | 5 | 100.0 |
Cytoskeleton/metabolism | 6 | 2.0 |
DNA, Antisense/*genetics | 2 | 15.0 |
Leukemia, Promyelocytic, Acute/genetics | 2 | 16.0 |
Oncogene Proteins/biosynthesis/*genetics | 2 | 18.0 |
Astrocytoma/*genetics/metabolism | 2 | 33.0 |
Chromosomes, Human, Pair 17 | 6 | 1.0 |
Chromosomes, Human, Pair 9 | 4 | 2.0 |
Protein p53/biosynthesis/genetics | 2 | 4.0 |
Guanosine Diphosphate/metabolism | 2 | 1.0 |
Alternative Splicing/genetics | 2 | 1.0 |
DNA, Satellite/analysis | 3 | 9.0 |
1-Phosphatidylinositol 3-Kinase/genetics/*metabolism | 2 | 13.0 |
Lysophospholipids/pharmacology | 2 | 4.0 |
Phosphatidylinositols/metabolism | 2 | 1.0 |
Phosphoproteins/*metabolism | 7 | 1.0 |
Administration, Topical | 2 | 1.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
Stomach Neoplasms/*blood/pathology | 2 | 15.0 |
Ki-67 Antigen/*biosynthesis | 2 | 7.0 |
Protein p53/*analysis/biosynthesis | 3 | 50.0 |
Receptor, Epidermal Growth Factor/*analysis/biosynthesis | 6 | 66.0 |
Thyroid Neoplasms/*pathology | 2 | 10.0 |
Receptor, erbB-2/chemistry/drug effects/*metabolism | 2 | 100.0 |
Ligases/*metabolism | 2 | 2.0 |
*Ubiquitin-Conjugating Enzymes | 2 | 2.0 |
Zinc Fingers | 2 | 0.0 |
Receptor, erbB-3/*physiology | 2 | 40.0 |
Cisplatin/toxicity | 2 | 10.0 |
Head and Neck Neoplasms/pathology | 3 | 18.0 |
Glioma/*genetics/pathology | 12 | 36.0 |
Nuclear Proteins/*analysis | 14 | 7.0 |
Breast Neoplasms/*enzymology | 2 | 3.0 |
Receptor, Epidermal Growth Factor/metabolism/*physiology | 9 | 56.0 |
Receptors, Growth Factor/metabolism | 4 | 3.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Signal Transduction/genetics | 8 | 3.0 |
Adenoviridae/*genetics | 3 | 1.0 |
Cytoplasm/*metabolism | 3 | 2.0 |
Japan/epidemiology | 2 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics/*physiology | 2 | 4.0 |
Proto-Oncogene Proteins c-raf/antagonists & inhibitors/metabolism | 2 | 33.0 |
Phenylalanine/chemistry | 2 | 6.0 |
Ubiquitin-Protein Ligases/*metabolism | 5 | 20.0 |
Astrocytoma/genetics | 2 | 8.0 |
Brain Neoplasms/classification/*genetics | 2 | 66.0 |
Adenocarcinoma/metabolism/pathology | 7 | 12.0 |
Fixatives | 5 | 6.0 |
Lung Neoplasms/metabolism/pathology | 2 | 11.0 |
Neoplasms/*metabolism/pathology | 2 | 6.0 |
Paraffin | 4 | 8.0 |
Tissue Embedding | 3 | 11.0 |
*Helicobacter pylori | 3 | 2.0 |
Receptors, Transforming Growth Factor beta/analysis | 2 | 18.0 |
*Cell Division | 2 | 1.0 |
DNA, Complementary/chemistry | 2 | 1.0 |
Antibodies, Monoclonal/chemistry | 3 | 3.0 |
*Drug Design | 4 | 4.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/chemistry | 2 | 40.0 |
Transferrin/metabolism | 2 | 1.0 |
Breast Neoplasms/*chemistry/mortality/therapy | 2 | 66.0 |
Cathepsin D/*analysis | 9 | 45.0 |
Pancreatic Neoplasms/*therapy | 2 | 22.0 |
Adenocarcinoma/enzymology/metabolism/pathology | 2 | 66.0 |
Breast Neoplasms/*enzymology/metabolism/pathology | 4 | 50.0 |
Hysterectomy | 4 | 5.0 |
Adenoma/chemistry/pathology | 2 | 40.0 |
Collagen/analysis | 3 | 4.0 |
Frozen Sections | 6 | 7.0 |
*Mitogen-Activated Protein Kinases | 6 | 1.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Mouth Neoplasms/*genetics/pathology | 3 | 16.0 |
*Gene Expression | 19 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/physiology | 2 | 5.0 |
DNA-Binding Proteins/analysis | 2 | 2.0 |
Mitogen-Activated Protein Kinase 1 | 6 | 4.0 |
Trans-Activators/analysis | 4 | 13.0 |
src-Family Kinases/*physiology | 3 | 7.0 |
RNA, Neoplasm/genetics/metabolism | 3 | 2.0 |
Antineoplastic Agents/chemical synthesis/*pharmacology | 3 | 33.0 |
Pancreatic Neoplasms/*metabolism/pathology | 5 | 10.0 |
beta-Galactosidase/genetics/metabolism | 2 | 3.0 |
*Carcinogens | 2 | 6.0 |
Cell Adhesion Molecules/*metabolism | 4 | 1.0 |
Antigens, Tumor-Associated, Carbohydrate/analysis | 2 | 10.0 |
CA-19-9 Antigen/analysis | 2 | 15.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Carcinoma, Squamous Cell/metabolism/pathology/radiotherapy | 2 | 100.0 |
*Mitogen-Activated Protein Kinase Kinases | 2 | 2.0 |
Recombinant Proteins/genetics/metabolism | 9 | 1.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 7 | 8.0 |
Ki-67 Antigen/*metabolism | 4 | 8.0 |
Laryngeal Neoplasms/*metabolism/pathology | 2 | 20.0 |
DNA/*biosynthesis | 3 | 3.0 |
Isotope Labeling | 2 | 2.0 |
Epidermal Growth Factor/antagonists & inhibitors | 12 | 57.0 |
Dyes/pharmacology | 3 | 3.0 |
Hepatocytes/*metabolism | 2 | 4.0 |
Metalloendopeptidases/metabolism | 2 | 3.0 |
Enzyme Induction | 5 | 0.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 3 | 2.0 |
Immunoassay | 4 | 1.0 |
Carcinoma, Squamous Cell/*enzymology/pathology | 2 | 14.0 |
Adenocarcinoma/*chemistry | 7 | 46.0 |
*Receptors, Fibroblast Growth Factor | 2 | 15.0 |
Receptors, Growth Factor/analysis | 2 | 7.0 |
*Membrane Glycoproteins | 6 | 0.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Epithelium/metabolism/pathology | 5 | 7.0 |
Carcinoma/*drug therapy/*metabolism | 2 | 66.0 |
*Transplantation, Heterologous | 3 | 4.0 |
Esophagectomy | 2 | 14.0 |
Neoplasms/therapy | 2 | 4.0 |
Wound Healing | 3 | 2.0 |
Cell Size/drug effects | 2 | 2.0 |
Trans-Activators/metabolism | 9 | 0.0 |
Carcinoma/*genetics/metabolism | 2 | 6.0 |
Cyclin-Dependent Kinases/metabolism | 3 | 0.0 |
*Neoplasm Recurrence, Local | 4 | 8.0 |
Pancreatic Neoplasms/*chemistry | 3 | 30.0 |
Injections | 2 | 1.0 |
Injections, Intravenous | 2 | 0.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Cadherins/*analysis | 3 | 13.0 |
Lymph Nodes/pathology | 8 | 2.0 |
Carcinoma, Hepatocellular/*genetics/pathology | 2 | 9.0 |
Liver Neoplasms/*genetics/pathology | 2 | 8.0 |
*Monomeric GTP-Binding Proteins | 2 | 4.0 |
Skin Neoplasms/*chemically induced | 2 | 40.0 |
Cell Polarity/*physiology | 2 | 8.0 |
Receptor, Epidermal Growth Factor/genetics/immunology/*metabolism | 7 | 77.0 |
Genes, fos | 3 | 2.0 |
Genes, myc | 9 | 3.0 |
Immune Sera | 2 | 0.0 |
Proto-Oncogene Proteins/genetics/immunology/*metabolism | 3 | 42.0 |
Cervix Neoplasms/*genetics | 2 | 7.0 |
Carcinoma, Non-Small-Cell Lung/diagnosis/*metabolism | 2 | 66.0 |
Lung Neoplasms/diagnosis/*metabolism | 2 | 66.0 |
Clathrin/*metabolism | 3 | 7.0 |
Receptors, Transferrin/metabolism | 4 | 5.0 |
Imidazoles/pharmacology | 3 | 1.0 |
Protein Subunits/metabolism | 2 | 4.0 |
Pyridines/pharmacology | 3 | 1.0 |
Mouth Neoplasms/*drug therapy | 2 | 40.0 |
Epithelial Cells/cytology/drug effects/physiology | 2 | 25.0 |
DNA, Neoplasm/*genetics | 8 | 3.0 |
Cell Cycle Proteins/*genetics | 2 | 1.0 |
*Chromosome Mapping | 4 | 0.0 |
RNA, Messenger/*analysis | 11 | 2.0 |
Meningeal Neoplasms/*genetics | 2 | 7.0 |
Meningioma/*genetics | 2 | 6.0 |
*Gene Deletion | 8 | 0.0 |
Angiogenesis Inducing Agents | 2 | 20.0 |
*Cloning, Molecular | 2 | 0.0 |
Escherichia coli/genetics | 3 | 0.0 |
Immunophenotyping | 4 | 0.0 |
Breast Neoplasms/drug therapy/metabolism | 2 | 22.0 |
Receptor, Epidermal Growth Factor/*analysis/metabolism | 8 | 53.0 |
Bronchi/*metabolism | 3 | 9.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Actuarial Analysis | 2 | 2.0 |
Oncogene Proteins/analysis | 4 | 36.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Luminescent Proteins/genetics/*metabolism | 2 | 18.0 |
Tissue Fixation/*methods | 2 | 13.0 |
Lung Neoplasms/pathology/secondary | 2 | 15.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism | 3 | 50.0 |
Adenocarcinoma/*metabolism/pathology | 10 | 8.0 |
Tumor Markers, Biological/analysis/*biosynthesis | 3 | 21.0 |
Hydrogen Bonding | 4 | 2.0 |
Brain Neoplasms/genetics/metabolism/pathology | 2 | 33.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
NF-kappa B/genetics/*metabolism | 3 | 4.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Tumor Suppressor Proteins/genetics | 3 | 4.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
Bromodeoxyuridine/diagnostic use | 2 | 9.0 |
Protein Precursors/analysis | 2 | 4.0 |
Clinical Trials, Phase II | 6 | 11.0 |
Clinical Trials, Phase III | 8 | 19.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology | 4 | 16.0 |
*RNA Interference | 2 | 5.0 |
Retinoblastoma Protein/*metabolism | 3 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 5 | 7.0 |
Carcinoma, Squamous Cell/genetics | 3 | 5.0 |
Genes, bcl-1/*genetics | 2 | 16.0 |
Lung Neoplasms/*genetics | 6 | 2.0 |
RNA, Neoplasm/analysis | 13 | 4.0 |
*Models, Biological | 6 | 3.0 |
Genes, myc/physiology | 2 | 20.0 |
Skin/chemistry | 3 | 8.0 |
Carcinoma, Squamous Cell/*metabolism/pathology/surgery | 2 | 33.0 |
Immunoglobulin G/*therapeutic use | 2 | 5.0 |
Binding Sites/drug effects | 2 | 3.0 |
Neoplasms, Hormone-Dependent/*pathology | 2 | 11.0 |
Mitogens/metabolism | 2 | 8.0 |
Phosphotyrosine/analysis | 5 | 8.0 |
Protein Binding/genetics | 3 | 1.0 |
Gene Expression/genetics | 6 | 2.0 |
Protein Processing, Post-Translational/drug effects | 2 | 1.0 |
Receptor, erbB-2/physiology | 5 | 62.0 |
Receptors, Interleukin-6/*biosynthesis | 2 | 50.0 |
Transforming Growth Factor alpha/*biosynthesis/pharmacology | 2 | 100.0 |
Carcinoma, Non-Small-Cell Lung | 3 | 15.0 |
DNA, Neoplasm/biosynthesis | 5 | 4.0 |
Colorectal Neoplasms/*chemistry/pathology | 5 | 31.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Peptide Fragments/metabolism/pharmacology | 2 | 6.0 |
Neoplasms/*etiology | 3 | 11.0 |
Transcription Factors/*physiology | 3 | 0.0 |
Brain Neoplasms/*genetics/mortality/pathology | 2 | 50.0 |
Oligodendroglioma/*genetics/mortality/pathology | 2 | 100.0 |
Proto-Oncogene Protein c-met/*genetics | 2 | 16.0 |
Genes, Retinoblastoma/genetics | 3 | 9.0 |
Rats, Inbred Strains | 4 | 0.0 |
Ascites | 2 | 18.0 |
DNA, Neoplasm/*metabolism | 2 | 6.0 |
Prostatic Neoplasms/*enzymology/pathology | 2 | 18.0 |
Proto-Oncogene Proteins c-raf/metabolism | 4 | 4.0 |
Formaldehyde | 6 | 6.0 |
Paraffin Embedding | 13 | 5.0 |
Recombinant Proteins/genetics | 4 | 3.0 |
Autoradiography | 4 | 0.0 |
Prostate/*metabolism | 3 | 4.0 |
Prostatic Hyperplasia/*metabolism | 5 | 10.0 |
Oligonucleotides, Antisense/pharmacology | 4 | 1.0 |
*Receptor, Epidermal Growth Factor | 2 | 28.0 |
Carcinoma/immunology | 2 | 13.0 |
Receptor, erbB-3 | 18 | 20.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Phosphopeptides/chemistry | 2 | 10.0 |
*Chromosome Deletion | 7 | 0.0 |
Calcium-Binding Proteins/*metabolism | 3 | 3.0 |
Nerve Tissue Proteins/metabolism | 3 | 1.0 |
Chelating Agents/pharmacology | 2 | 2.0 |
Egtazic Acid/analogs & derivatives/pharmacology | 2 | 7.0 |
Carcinoma, Squamous Cell/*drug therapy/pathology | 3 | 30.0 |
Cell Death | 6 | 1.0 |
Epidermal Growth Factor/*genetics | 9 | 12.0 |
*Immunotoxins | 2 | 16.0 |
Protein Folding | 2 | 0.0 |
Antigens, Nuclear | 3 | 2.0 |
Cadherins/metabolism | 6 | 4.0 |
Ki-67 Antigen | 31 | 14.0 |
Nuclear Proteins/metabolism | 14 | 1.0 |
Prostatic Hyperplasia/metabolism | 2 | 6.0 |
Receptors, Androgen/*metabolism | 2 | 1.0 |
Cell Nucleus/chemistry | 5 | 2.0 |
Gene Targeting/*methods | 3 | 14.0 |
Protein-Tyrosine Kinase/genetics | 5 | 4.0 |
Simplexvirus/genetics | 2 | 9.0 |
Tumor Cells, Cultured/enzymology | 2 | 5.0 |
Receptors, Growth Factor/*metabolism | 9 | 8.0 |
Receptors, Somatostatin/metabolism | 2 | 11.0 |
Receptors, Transforming Growth Factor beta/metabolism | 2 | 4.0 |
Cell Fractionation | 4 | 1.0 |
Glial Fibrillary Acidic Protein/biosynthesis | 2 | 10.0 |
Detergents/pharmacology | 4 | 3.0 |
Embryonic and Fetal Development | 3 | 0.0 |
Mice, Knockout | 12 | 0.0 |
Receptor, Epidermal Growth Factor/deficiency/genetics/*physiology | 2 | 50.0 |
Tetrachlorodibenzodioxin/*toxicity | 3 | 6.0 |
Glioma/*metabolism/pathology | 2 | 7.0 |
Kidney Neoplasms/*metabolism/pathology | 2 | 6.0 |
Evaluation Studies | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 4 | 6.0 |
Oligonucleotides/chemistry | 2 | 1.0 |
Quinolines/*pharmacology | 2 | 6.0 |
Gene Silencing | 3 | 0.0 |
Heparin/*metabolism | 2 | 2.0 |
Osmotic Pressure | 2 | 3.0 |
RNA, Small Interfering/genetics | 3 | 2.0 |
Promoter Regions (Genetics)/drug effects | 2 | 1.0 |
Collagen/metabolism | 5 | 1.0 |
Culture Media, Conditioned | 3 | 0.0 |
Estrogen Antagonists/pharmacology | 2 | 2.0 |
Laminin/metabolism | 2 | 1.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Drosophila melanogaster | 2 | 1.0 |
Membrane Proteins/*chemistry | 3 | 7.0 |
*Contrast Media | 2 | 7.0 |
Vimentin/biosynthesis | 2 | 14.0 |
Breast Neoplasms/drug therapy/pathology | 2 | 28.0 |
Lung Neoplasms/drug therapy/pathology | 2 | 28.0 |
Neoplasms/*drug therapy/pathology | 4 | 23.0 |
Epithelial Cells/cytology/*metabolism | 3 | 10.0 |
Receptor, Epidermal Growth Factor/*metabolism/ultrastructure | 2 | 100.0 |
Genistein/*pharmacology | 2 | 6.0 |
Membranes/metabolism | 3 | 6.0 |
Epidermal Growth Factor/genetics/pharmacology | 2 | 40.0 |
*Neuregulin-1 | 2 | 7.0 |
Antigens, CD3/analysis | 2 | 0.0 |
Antigens, CD4/analysis | 2 | 0.0 |
Flow Cytometry/*methods | 3 | 1.0 |
Microspheres | 2 | 1.0 |
Receptors, Cell Surface/*analysis | 5 | 4.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Streptavidin | 2 | 12.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Bladder/pathology | 2 | 13.0 |
Epithelium/metabolism | 17 | 4.0 |
Immunosorbent Techniques | 3 | 1.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Breast Neoplasms/*genetics/pathology | 5 | 2.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 2 | 7.0 |
Carcinoma, Intraductal, Noninfiltrating/*genetics/pathology | 2 | 28.0 |
Phosphotyrosine | 7 | 2.0 |
Glioblastoma/*therapy | 2 | 100.0 |
Epidermal Growth Factor/biosynthesis | 2 | 16.0 |
Gene Expression Regulation/genetics | 4 | 2.0 |
Nuclear Proteins/analysis | 15 | 8.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Trans-Activation (Genetics)/*genetics | 2 | 2.0 |
Transcription, Genetic/genetics | 4 | 1.0 |
GTPase-Activating Proteins | 2 | 1.0 |
Kidney/cytology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/drug effects | 3 | 50.0 |
Carcinoma, Squamous Cell/*radionuclide imaging | 2 | 40.0 |
Iodine Radioisotopes/*diagnostic use | 2 | 3.0 |
Liver Neoplasms/pathology/secondary | 2 | 20.0 |
Prostatic Neoplasms/*pathology | 4 | 3.0 |
Antibodies, Monoclonal/*toxicity | 2 | 25.0 |
Neoplasm Proteins/*immunology | 3 | 8.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Neoplasm Proteins/*biosynthesis/genetics | 4 | 2.0 |
Liver/metabolism/pathology | 2 | 4.0 |
Transforming Growth Factor alpha/*analysis/genetics | 3 | 60.0 |
Receptor, Epidermal Growth Factor/biosynthesis/genetics/physiology | 2 | 100.0 |
Carcinoma, Medullary/*pathology | 2 | 66.0 |
Proto-Oncogene Proteins/analysis/*genetics | 3 | 6.0 |
Aging/physiology | 2 | 1.0 |
Survival | 2 | 5.0 |
Actins/*metabolism | 5 | 2.0 |
Calcium-Binding Proteins/metabolism | 2 | 2.0 |
Embryo | 3 | 0.0 |
Clinical Trials, Phase I | 6 | 10.0 |
Neovascularization, Pathologic/*pathology | 2 | 1.0 |
Cadherins/biosynthesis | 2 | 7.0 |
Cell Adhesion/physiology | 3 | 1.0 |
NIH 3T3 Cells | 13 | 4.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Breast/*metabolism | 3 | 5.0 |
Oligonucleotide Probes | 8 | 1.0 |
Bronchi/*physiology | 2 | 25.0 |
Tretinoin/*pharmacology | 6 | 1.0 |
Transforming Growth Factor alpha/pharmacology/*physiology | 2 | 66.0 |
Oncogenes/genetics | 4 | 5.0 |
Receptor, Epidermal Growth Factor/*analysis/immunology | 8 | 53.0 |
Neoplasm Recurrence, Local/*genetics | 3 | 18.0 |
Phosphopeptides/metabolism | 3 | 10.0 |
Stomach Neoplasms/*genetics/metabolism/pathology | 3 | 20.0 |
Feasibility Studies | 2 | 0.0 |
*N-Glycosyl Hydrolases | 2 | 3.0 |
Oxidants/pharmacology | 2 | 3.0 |
Proto-Oncogene Proteins c-fos/biosynthesis | 2 | 6.0 |
Proto-Oncogene Proteins c-myc/metabolism | 4 | 4.0 |
*Mouth Mucosa/metabolism | 2 | 100.0 |
Cyclins/*metabolism | 3 | 1.0 |
Enzyme Inhibitors/metabolism/pharmacology | 2 | 10.0 |
*Macrolides | 3 | 8.0 |
Epidermal Growth Factor/*genetics/metabolism | 5 | 31.0 |
DNA-Binding Proteins/*physiology | 5 | 0.0 |
Receptor, erbB-2/*analysis/biosynthesis | 2 | 100.0 |
Blotting, Southern/methods | 2 | 7.0 |
Receptor, Epidermal Growth Factor/*analysis/biosynthesis/genetics | 2 | 50.0 |
Recombinant Proteins/biosynthesis | 5 | 1.0 |
Ovarian Neoplasms/*drug therapy | 3 | 15.0 |
Antigens, CD/*genetics | 2 | 0.0 |
Epidermal Growth Factor/genetics | 6 | 8.0 |
Luciferases/genetics | 3 | 0.0 |
Precancerous Conditions/*pathology | 2 | 7.0 |
Collagenases/metabolism | 2 | 5.0 |
Subrenal Capsule Assay | 2 | 40.0 |
Chick Embryo | 5 | 0.0 |
Gene Rearrangement | 7 | 1.0 |
*Multigene Family | 3 | 0.0 |
RNA, Neoplasm/analysis/genetics | 3 | 15.0 |
Alanine/metabolism | 2 | 5.0 |
Crystallography, X-Ray | 7 | 0.0 |
Insulin/metabolism | 2 | 1.0 |
Insulin-Like Growth Factor I/metabolism | 3 | 1.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
*Phosphoric Monoester Hydrolases | 2 | 4.0 |
Binding Sites/physiology | 2 | 1.0 |
Phosphotyrosine/*metabolism | 2 | 3.0 |
Receptor Protein-Tyrosine Kinases/physiology | 2 | 4.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
*DNA, Antisense | 2 | 20.0 |
Astrocytoma/metabolism | 2 | 8.0 |
Cyclic AMP-Dependent Protein Kinases/*genetics | 2 | 12.0 |
Chimeric Proteins/genetics | 2 | 3.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
DNA/*metabolism | 3 | 0.0 |
Proliferating Cell Nuclear Antigen/genetics | 2 | 6.0 |
Prostatic Hyperplasia/*metabolism/pathology | 4 | 13.0 |
Prostatic Neoplasms/*metabolism/pathology | 4 | 5.0 |
Adenocarcinoma/genetics/*metabolism/pathology | 2 | 7.0 |
Head and Neck Neoplasms/genetics/*metabolism | 2 | 33.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
Glioma/genetics/*metabolism | 2 | 40.0 |
Colorectal Neoplasms/genetics/metabolism/*pathology | 2 | 16.0 |
Receptor, erbB-2/*analysis/genetics | 3 | 33.0 |
Radiation-Sensitizing Agents/*therapeutic use | 4 | 57.0 |
Transduction, Genetic/methods | 2 | 8.0 |
Cell Survival/radiation effects | 2 | 2.0 |
Neoplasm Recurrence, Local/metabolism | 3 | 23.0 |
Smoking/*adverse effects | 2 | 0.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 2 | 1.0 |
Signal Transduction/genetics/*physiology | 3 | 8.0 |
Oxidative Stress/drug effects | 2 | 4.0 |
Laryngeal Neoplasms/*metabolism | 3 | 23.0 |
Antibodies, Monoclonal/immunology/*therapeutic use | 2 | 6.0 |
Oncogene Proteins, Viral/genetics/*physiology | 2 | 25.0 |
Proto-Oncogene Proteins/drug effects/metabolism | 2 | 6.0 |
Receptor, erbB-2/drug effects/metabolism | 5 | 62.0 |
Circular Dichroism | 2 | 0.0 |
*Protein Conformation | 2 | 0.0 |
Receptor, Epidermal Growth Factor/immunology/*physiology | 2 | 28.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Interleukin-3/metabolism | 2 | 6.0 |
Tyrosine | 2 | 1.0 |
Breast Neoplasms/*drug therapy | 7 | 10.0 |
Macaca fascicularis | 3 | 1.0 |
*Dose Fractionation | 2 | 40.0 |
*Drug Resistance, Multiple | 2 | 1.0 |
Protein-Serine-Threonine Kinases/*biosynthesis | 2 | 6.0 |
Exfoliation Syndrome/metabolism/pathology | 2 | 12.0 |
Extracellular Matrix/metabolism/ultrastructure | 2 | 10.0 |
Ferritin/*metabolism | 2 | 7.0 |
Microscopy, Electron, Transmission | 2 | 4.0 |
Perfusion | 2 | 0.0 |
Trabecular Meshwork/*metabolism/ultrastructure | 2 | 11.0 |
Receptor, Epidermal Growth Factor/analysis/drug effects/*metabolism | 3 | 100.0 |
Carcinoembryonic Antigen/metabolism | 2 | 10.0 |
Cell Polarity | 4 | 3.0 |
Fibroblast Growth Factors/pharmacology | 3 | 4.0 |
Growth Substances/pharmacology | 2 | 1.0 |
RNA, Messenger | 5 | 1.0 |
Chemoprevention | 6 | 14.0 |
Herpesvirus 4, Human/*genetics | 2 | 2.0 |
Growth Inhibitors/*metabolism | 2 | 3.0 |
Ameloblastoma/*metabolism/pathology | 2 | 40.0 |
Mitogens/*pharmacology | 4 | 3.0 |
Growth Substances/*analysis | 8 | 25.0 |
Precancerous Conditions/*chemistry/pathology | 3 | 37.0 |
Breast Neoplasms/genetics/*pathology | 3 | 6.0 |
Cell Adhesion/*physiology | 2 | 1.0 |
RNA Splicing | 4 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Glioblastoma/*metabolism | 3 | 9.0 |
Dihydrotestosterone/*pharmacology | 2 | 6.0 |
Prostatic Neoplasms | 2 | 3.0 |
Hydroxyurea/*pharmacology | 2 | 14.0 |
Chromosome Banding | 4 | 0.0 |
Cell Division/drug effects/immunology | 2 | 3.0 |
Brain Neoplasms/genetics/*pathology | 2 | 28.0 |
Drug Resistance, Neoplasm/genetics | 3 | 4.0 |
Glioblastoma/genetics/metabolism/pathology | 2 | 20.0 |
Data Interpretation, Statistical | 5 | 2.0 |
Oligonucleotides, Antisense/genetics/pharmacology | 3 | 13.0 |
Receptor, Epidermal Growth Factor/chemistry/genetics/metabolism | 2 | 100.0 |
Breast Neoplasms/drug therapy | 2 | 6.0 |
Carcinoma, Ductal, Breast/genetics/metabolism/*pathology | 2 | 50.0 |
Proto-Oncogene Proteins c-myc | 2 | 5.0 |
Factor Xa/metabolism | 2 | 3.0 |
Neoplasms/metabolism | 4 | 4.0 |
Recombinant Proteins | 5 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/genetics/*physiology | 2 | 100.0 |
Radiation-Protective Agents/*pharmacology | 2 | 10.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 6 | 4.0 |
RNA, Messenger/biosynthesis/*genetics | 2 | 8.0 |
Dementia/*metabolism | 3 | 17.0 |
Creatinine/blood | 2 | 0.0 |
Bladder Neoplasms/*chemistry/pathology | 3 | 30.0 |
DNA, Neoplasm/*analysis | 15 | 8.0 |
Fluorescein-5-isothiocyanate | 2 | 1.0 |
Bladder/chemistry | 2 | 50.0 |
Bacteriophages | 2 | 13.0 |
*Depsipeptides | 3 | 10.0 |
Fibroblasts/cytology/drug effects/metabolism | 2 | 3.0 |
Mucins/*genetics | 2 | 1.0 |
Protein Engineering/methods | 2 | 12.0 |
*Point Mutation | 3 | 0.0 |
Cytoplasm/chemistry/metabolism | 2 | 11.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase | 3 | 8.0 |
GTP-Binding Protein alpha Subunits, Gi-Go/metabolism | 2 | 5.0 |
GTP-Binding Proteins/*metabolism | 4 | 1.0 |
Pyrimidines/pharmacology | 7 | 6.0 |
Nucleolus Organizer Region/pathology/ultrastructure | 2 | 100.0 |
Autoantigens/metabolism | 2 | 4.0 |
Receptor, Epidermal Growth Factor/chemistry/metabolism | 2 | 28.0 |
T-Lymphocytes/immunology/*metabolism | 2 | 2.0 |
Genes, fos/drug effects | 4 | 17.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Epidermal Growth Factor/*metabolism/physiology | 3 | 42.0 |
Alkyl and Aryl Transferases/antagonists & inhibitors | 2 | 28.0 |
RNA, Antisense | 3 | 5.0 |
Mucous Membrane/pathology | 2 | 5.0 |
Chromosomes, Human, Pair 7/genetics | 3 | 3.0 |
Epidermal Growth Factor/*therapeutic use | 2 | 10.0 |
Breast Neoplasms/drug therapy/*metabolism/pathology | 2 | 16.0 |
Receptor, erbB-2/*immunology | 2 | 11.0 |
Transforming Growth Factor alpha/*genetics/metabolism | 4 | 40.0 |
Ovary/pathology | 2 | 6.0 |
Mouth Mucosa/metabolism/pathology | 2 | 33.0 |
Mitosis/physiology | 2 | 2.0 |
Carcinoma, Squamous Cell/metabolism | 3 | 5.0 |
Stomach Neoplasms/*genetics | 4 | 3.0 |
Trans-Activation (Genetics)/physiology | 3 | 3.0 |
Cell Fusion | 3 | 1.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 2 | 2.0 |
Transfection/genetics | 2 | 1.0 |
*Potassium Channels, Voltage-Gated | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*physiology | 2 | 3.0 |
Carcinoma, Intraductal, Noninfiltrating/metabolism/pathology | 2 | 40.0 |
Breast Neoplasms/*chemistry/mortality/pathology | 6 | 30.0 |
Proto-Oncogene Proteins c-myc/*analysis/genetics | 2 | 66.0 |
Tumor Markers, Biological/*analysis/genetics | 3 | 8.0 |
DNA Methylation | 4 | 0.0 |
*Polymerase Chain Reaction | 5 | 2.0 |
*Caenorhabditis elegans Proteins | 2 | 1.0 |
Cytoskeletal Proteins/metabolism | 5 | 1.0 |
Neoplasms/etiology | 2 | 5.0 |
Proto-Oncogene Protein pp60(c-src)/*physiology | 4 | 66.0 |
Cell Membrane/drug effects/physiology | 2 | 11.0 |
Ionophores/pharmacology | 2 | 1.0 |
Nerve Growth Factors/pharmacology | 2 | 2.0 |
Kidney | 2 | 0.0 |
Oncogene Proteins/metabolism | 2 | 2.0 |
Carbachol/pharmacology | 3 | 3.0 |
Receptor, Epidermal Growth Factor/chemistry/*genetics/*metabolism | 2 | 50.0 |
Receptors, Muscarinic/*metabolism | 2 | 5.0 |
Proto-Oncogene Proteins c-raf | 3 | 2.0 |
*Tyrphostins | 11 | 21.0 |
Extracellular Matrix Proteins/*metabolism | 2 | 3.0 |
Binding Sites, Antibody | 2 | 0.0 |
Flow Cytometry/methods | 2 | 0.0 |
Genes, Wilms Tumor/*genetics | 3 | 4.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism | 3 | 11.0 |
Lung/metabolism | 4 | 2.0 |
Transforming Growth Factor alpha/*genetics | 9 | 19.0 |
Breast Neoplasms/genetics/*metabolism/*pathology | 4 | 26.0 |
Glycoproteins/*pharmacology | 4 | 4.0 |
Neuregulins | 6 | 10.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Carcinoma, Squamous Cell/*chemistry | 9 | 45.0 |
Estradiol/metabolism | 2 | 2.0 |
G1 Phase | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 7 | 4.0 |
Spodoptera | 2 | 0.0 |
Antibiotics, Antineoplastic/*therapeutic use | 2 | 8.0 |
Gene Expression/*genetics | 2 | 1.0 |
Cell Membrane/drug effects/*physiology | 2 | 25.0 |
Oncogene Proteins/genetics/*metabolism | 2 | 4.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 3 | 2.0 |
Antigens, Surface/immunology | 2 | 1.0 |
Signal Transduction/drug effects/physiology/radiation effects | 2 | 50.0 |
Epirubicin/administration & dosage | 2 | 5.0 |
Bladder Neoplasms/*chemistry | 4 | 66.0 |
Carcinoma, Transitional Cell/*chemistry | 3 | 60.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Brain Neoplasms/*genetics/metabolism/*pathology | 2 | 40.0 |
Brain Neoplasms/*radionuclide imaging | 3 | 50.0 |
Glioma/*radionuclide imaging | 3 | 75.0 |
Technetium/*diagnostic use | 2 | 8.0 |
Estradiol/*pharmacology/therapeutic use | 2 | 33.0 |
*Estrogen Replacement Therapy | 2 | 1.0 |
Chimeric Proteins/genetics/metabolism | 2 | 2.0 |
Gelatinases/metabolism | 2 | 6.0 |
Protease Inhibitors/metabolism | 3 | 10.0 |
Tissue Inhibitor of Metalloproteinases | 2 | 3.0 |
Gastrins/blood | 2 | 2.0 |
*Agglutinins | 3 | 10.0 |
Point Mutation/genetics | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Mechanotransduction, Cellular/*physiology | 2 | 28.0 |
Linear Models | 4 | 0.0 |
Receptor Aggregation | 2 | 2.0 |
Transforming Growth Factor alpha | 2 | 66.0 |
Prostatic Neoplasms/*chemistry/pathology | 2 | 9.0 |
Glycoproteins/*genetics | 2 | 1.0 |
Growth Substances/*genetics | 3 | 2.0 |
Monocytes/*metabolism | 2 | 0.0 |
Fenretinide/*pharmacology | 2 | 25.0 |
Transforming Growth Factor alpha/analysis/*biosynthesis | 5 | 62.0 |
Estradiol/blood | 3 | 0.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Ovary/*metabolism | 2 | 3.0 |
Progesterone/blood | 3 | 1.0 |
RNA, Neoplasm/metabolism | 3 | 3.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Neoplasms/*immunology | 2 | 1.0 |
Epithelial Cells/cytology/*physiology | 2 | 16.0 |
Mammary Glands, Human/*cytology | 2 | 40.0 |
Transforming Growth Factor alpha/genetics/metabolism | 5 | 41.0 |
Breast Neoplasms/metabolism/pathology | 2 | 5.0 |
Neuregulin-1/physiology | 2 | 50.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Antimetabolites, Antineoplastic/pharmacology | 3 | 3.0 |
Carcinoma/pathology | 2 | 4.0 |
Epitopes/immunology | 2 | 0.0 |
Cell Adhesion/genetics | 2 | 3.0 |
Genes, erbB-2/*physiology | 2 | 25.0 |
Cell Membrane/ultrastructure | 2 | 4.0 |
Cytoplasm/ultrastructure | 4 | 6.0 |
Dyes/diagnostic use | 3 | 3.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Epithelium/chemistry/pathology | 4 | 11.0 |
Laryngeal Neoplasms/*chemistry/pathology | 3 | 50.0 |
Carcinoma, Squamous Cell/chemistry/*pathology | 2 | 40.0 |
Precancerous Conditions/chemistry/*pathology | 2 | 28.0 |
Receptors, Steroid/analysis | 2 | 18.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Protein p53/analysis/*biosynthesis | 2 | 9.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 2 | 8.0 |
Carcinoma/*drug therapy | 3 | 23.0 |
Ovarian Neoplasms/*chemistry | 5 | 38.0 |
Adenocarcinoma/*chemistry/pathology | 5 | 11.0 |
Ovarian Neoplasms/*chemistry/*pathology | 2 | 33.0 |
Transforming Growth Factor alpha/analysis/biosynthesis | 2 | 66.0 |
Herpesvirus 4, Human/*metabolism | 2 | 4.0 |
Viral Matrix Proteins/genetics/*metabolism | 2 | 10.0 |
Genistein | 3 | 4.0 |
Isoflavones/*pharmacology | 2 | 8.0 |
Nitriles/*pharmacology | 3 | 13.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/physiology | 2 | 50.0 |
1-Phosphatidylinositol 3-Kinase | 3 | 2.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Adenocarcinoma/metabolism/*pathology | 3 | 5.0 |
Stomach Neoplasms/metabolism/*pathology | 4 | 12.0 |
Human Growth Hormone/*pharmacology | 4 | 10.0 |
Forecasting | 4 | 1.0 |
Epidermal Growth Factor/analysis/genetics | 2 | 66.0 |
Tissue Fixation | 3 | 3.0 |
Epidermal Growth Factor/*chemistry | 3 | 5.0 |
Transforming Growth Factor alpha/*chemistry | 2 | 33.0 |
Papillomavirus, Human | 3 | 8.0 |
Immunization, Passive | 2 | 2.0 |
*Chromosomes | 2 | 3.0 |
Base Composition | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 2 | 1.0 |
WT1 Proteins | 2 | 0.0 |
DNA Probes | 20 | 1.0 |
Calcium/pharmacology | 3 | 1.0 |
*Proteins | 6 | 1.0 |
Tumor Necrosis Factor-alpha/*analysis | 3 | 1.0 |
Carcinoma, Ductal, Breast/*chemistry/pathology | 2 | 15.0 |
Prostatic Neoplasms/*metabolism/*pathology | 2 | 11.0 |
Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use | 2 | 20.0 |
Exotoxins/*therapeutic use | 2 | 50.0 |
Immunotoxins/*therapeutic use | 4 | 8.0 |
Recombinant Fusion Proteins/*therapeutic use | 2 | 10.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Antigens, Neoplasm/analysis | 6 | 1.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/*drug effects/*metabolism | 2 | 66.0 |
Hybrid Cells | 3 | 0.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 3 | 1.0 |
Receptors, Antigen, T-Cell/*metabolism | 2 | 1.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
RNA/genetics | 2 | 1.0 |
Protein Binding/physiology | 4 | 1.0 |
Glioma/*genetics/*pathology | 2 | 33.0 |
Molecular Probes/genetics | 2 | 2.0 |
Receptor, Epidermal Growth Factor/*biosynthesis/*drug effects | 2 | 100.0 |
Genes, erbB-1/*drug effects/genetics | 2 | 100.0 |
Cluster Analysis | 3 | 1.0 |
Antibodies, Monoclonal/administration & dosage/therapeutic use | 2 | 50.0 |
Adipocytes/metabolism | 3 | 7.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
DNA, Neoplasm/isolation & purification | 2 | 6.0 |
RNA, Neoplasm/isolation & purification | 2 | 6.0 |
Lung Neoplasms/*chemistry/pathology/ultrastructure | 2 | 100.0 |
Oligonucleotides, Antisense/*administration & dosage | 2 | 40.0 |
Remission Induction | 2 | 0.0 |
Spectrometry, Fluorescence/methods | 2 | 7.0 |
DNA/analysis | 9 | 1.0 |
Colorectal Neoplasms/*metabolism | 4 | 9.0 |
*Antibodies, Monoclonal | 5 | 2.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Receptor, Epidermal Growth Factor/analysis/*genetics/*immunology | 2 | 100.0 |
Lysosomes/*metabolism | 5 | 6.0 |
Carcinoma/*chemistry/genetics | 3 | 60.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
Genes, jun | 2 | 2.0 |
Glutathione Transferase/biosynthesis | 2 | 6.0 |
Prostatic Neoplasms/*pathology/*physiopathology | 2 | 100.0 |
Extracellular Space/metabolism | 2 | 3.0 |
Growth Substances/*biosynthesis/genetics | 2 | 7.0 |
Guanine Nucleotide Exchange Factors | 2 | 2.0 |
ras Guanine Nucleotide Exchange Factors | 2 | 3.0 |
Carcinoma, Endometrioid/*chemistry/pathology | 4 | 100.0 |
Staining and Labeling/methods | 3 | 2.0 |
Breast Neoplasms/chemistry/mortality/*pathology | 2 | 66.0 |
Receptors, Estradiol/*analysis | 4 | 50.0 |
Estradiol/*analogs & derivatives/pharmacology | 2 | 4.0 |
Breast Neoplasms/*pathology/*physiopathology | 2 | 40.0 |
Carcinoma, Non-Small-Cell Lung/*chemistry | 5 | 71.0 |
Lung Neoplasms/*chemistry | 6 | 33.0 |
Carcinoma, Transitional Cell/*chemistry/pathology | 2 | 28.0 |
Oncogene Proteins/*analysis | 2 | 25.0 |
Astrocytoma/*chemistry/genetics | 2 | 100.0 |
Transforming Growth Factor alpha/metabolism/*pharmacology | 2 | 50.0 |
Endometrial Hyperplasia/metabolism/pathology | 2 | 28.0 |
Endometrial Neoplasms/*chemistry/pathology | 3 | 27.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Growth Substances/*pharmacology | 5 | 1.0 |
Sepharose/chemistry | 2 | 18.0 |
*Wound Healing | 2 | 3.0 |
Antigens, CD95/*metabolism | 3 | 2.0 |
Receptor, Epidermal Growth Factor/drug effects/genetics/*metabolism | 2 | 16.0 |
Antigens, Polyomavirus Transforming/*genetics | 2 | 7.0 |
DNA, Recombinant/analysis | 2 | 10.0 |
Bile Duct Neoplasms/*metabolism/pathology | 2 | 33.0 |
Heparin/metabolism | 3 | 2.0 |
Microscopy, Electron, Scanning | 6 | 2.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Thyroid Neoplasms/*metabolism/pathology | 3 | 6.0 |
Enzyme Inhibitors/chemical synthesis/chemistry/pharmacology | 2 | 66.0 |
Colonic Neoplasms/*genetics/metabolism/pathology | 4 | 21.0 |
Crosses, Genetic | 3 | 0.0 |
Cyprinodontiformes/*genetics | 2 | 20.0 |
Linkage (Genetics) | 2 | 0.0 |
Cathepsin D/*metabolism | 4 | 26.0 |
Brain Neoplasms/metabolism/*radiotherapy | 2 | 100.0 |
Glioblastoma/metabolism/*pathology | 3 | 37.0 |
Receptor, IGF Type 1/*analysis | 2 | 33.0 |
Receptor, Epidermal Growth Factor/biosynthesis/metabolism/*physiology | 2 | 100.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Uterine Neoplasms/*genetics/pathology | 2 | 16.0 |
Receptors, Estradiol/analysis | 3 | 27.0 |
Peptides/*metabolism | 2 | 1.0 |
Intercellular Signaling Peptides and Proteins/metabolism | 4 | 5.0 |
Naphthalenes/pharmacology | 2 | 2.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/physiopathology | 3 | 100.0 |
Lung Neoplasms/*drug therapy/physiopathology | 3 | 42.0 |
Adenoma/*metabolism | 4 | 7.0 |
Glycogen Synthase Kinase 3/metabolism | 3 | 9.0 |
Carcinoma/*chemistry/mortality/pathology | 4 | 100.0 |
Glioma/*genetics/metabolism | 3 | 23.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Goserelin/*therapeutic use | 2 | 25.0 |
Neoplasm Proteins/analysis/*biosynthesis/genetics | 2 | 22.0 |
Protein p53/*biosynthesis/genetics | 2 | 5.0 |
Carcinoma/genetics/*pathology | 2 | 22.0 |
Injections, Subcutaneous | 2 | 0.0 |
Glioblastoma/genetics/mortality | 2 | 100.0 |
HL-60 Cells | 3 | 0.0 |
Tumor Cells, Cultured/*drug effects | 2 | 4.0 |
Recombinant Proteins/biosynthesis/isolation & purification/metabolism | 2 | 3.0 |
Gene Expression/*drug effects | 5 | 2.0 |
Methylation | 3 | 0.0 |
Receptors, Estrogen/*genetics | 3 | 3.0 |
Glioma/*pathology | 3 | 5.0 |
Colon/*metabolism | 2 | 3.0 |
Down-Regulation/physiology | 2 | 2.0 |
Sepharose | 2 | 3.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
*Lymphatic Metastasis | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2 | 4 | 2.0 |
Proliferating Cell Nuclear Antigen/*analysis | 5 | 2.0 |
Neoplasms, Hormone-Dependent/*metabolism/pathology | 2 | 40.0 |
Mammary Neoplasms, Experimental/*pathology | 2 | 12.0 |
Glycoproteins/pharmacology | 3 | 7.0 |
Catechols/pharmacology | 3 | 16.0 |
Phosphoproteins/isolation & purification/metabolism | 2 | 5.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Tyrosine/analogs & derivatives/metabolism | 3 | 2.0 |
Prostate/metabolism | 2 | 2.0 |
Receptors, Androgen/metabolism | 4 | 9.0 |
Apoptosis/drug effects/genetics | 3 | 8.0 |
RNA/analysis | 5 | 2.0 |
Breast/*chemistry | 3 | 13.0 |
Cell Death/drug effects | 2 | 1.0 |
Proto-Oncogenes/*genetics | 6 | 8.0 |
Genes, Structural | 5 | 0.0 |
Extracellular Matrix/metabolism | 3 | 1.0 |
Cobalt Radioisotopes | 2 | 9.0 |
Proto-Oncogene Protein p21(ras)/analysis | 3 | 50.0 |
Receptor, Epidermal Growth Factor/analysis/*physiology | 7 | 58.0 |
Epidermal Growth Factor/pharmacology/*physiology | 2 | 6.0 |
Prostate/chemistry | 2 | 10.0 |
Lymphatic Metastasis/*pathology | 2 | 5.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/*drug effects | 2 | 100.0 |
Glioma/drug therapy/*pathology | 2 | 66.0 |
Menstrual Cycle/*physiology | 2 | 3.0 |
Tyrosine/*analogs & derivatives/metabolism | 2 | 3.0 |
*Lung Neoplasms | 5 | 21.0 |
Tyrosine/analogs & derivatives/analysis | 2 | 5.0 |
Transforming Growth Factor alpha/metabolism/pharmacology | 2 | 33.0 |
Gene Expression Regulation/drug effects/*physiology | 2 | 2.0 |
Carcinoma, Squamous Cell/genetics/*pathology | 2 | 11.0 |
Antibodies, Neoplasm/pharmacology | 2 | 66.0 |
Nitrosourea Compounds/*pharmacology | 2 | 28.0 |
Reactive Oxygen Species/*metabolism | 2 | 1.0 |
Menstrual Cycle | 2 | 1.0 |
Adenocarcinoma/metabolism | 2 | 2.0 |
Metalloendopeptidases/antagonists & inhibitors | 2 | 9.0 |
Antineoplastic Agents, Hormonal/pharmacology | 3 | 6.0 |
Receptor Cross-Talk | 3 | 7.0 |
RNA Probes | 3 | 2.0 |
CA-15-3 Antigen | 3 | 3.0 |
Proto-Oncogene Proteins/*analysis | 17 | 10.0 |
Matched-Pair Analysis | 2 | 2.0 |
Biological Assay | 2 | 0.0 |
Keratinocytes/drug effects/*metabolism | 2 | 7.0 |
Brain Neoplasms/metabolism/*pathology | 2 | 8.0 |
Isoflavones/pharmacology | 2 | 3.0 |
Cyclooxygenase Inhibitors/therapeutic use | 2 | 18.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
rac1 GTP-Binding Protein/metabolism | 2 | 2.0 |
Codon | 3 | 0.0 |
Endometrial Neoplasms/*chemistry/mortality/pathology | 3 | 75.0 |
Menstrual Cycle/*metabolism | 2 | 6.0 |
Myometrium/*metabolism | 3 | 11.0 |
Cell Transformation, Neoplastic/metabolism/pathology | 2 | 14.0 |
Prostatic Hyperplasia/*pathology | 2 | 10.0 |
Prostatic Neoplasms/chemistry/*pathology | 2 | 16.0 |
Receptor, Epidermal Growth Factor/analysis/*drug effects | 3 | 33.0 |
Receptors, Estrogen/analysis/*drug effects | 2 | 66.0 |
Receptors, Progesterone/analysis/*drug effects | 2 | 100.0 |
Proliferating Cell Nuclear Antigen | 12 | 5.0 |
Cell Transformation, Neoplastic/*pathology | 2 | 7.0 |
Culture Media, Conditioned/chemistry | 2 | 4.0 |
*Flow Cytometry | 2 | 1.0 |
Diethylnitrosamine | 2 | 28.0 |
Carcinoma/*chemistry | 2 | 16.0 |
Carcinoma, Squamous Cell/chemistry | 2 | 22.0 |
Neoplasms/drug therapy/metabolism | 2 | 11.0 |
Nervous System Neoplasms/*genetics | 2 | 18.0 |
Pancreatic Neoplasms/*genetics | 2 | 2.0 |
Colonic Neoplasms/*genetics/pathology | 2 | 4.0 |
Cell Communication/physiology | 2 | 2.0 |
Receptor, Epidermal Growth Factor/analysis/physiology | 2 | 50.0 |
Receptors, Cell Surface/analysis | 2 | 2.0 |
Adenocarcinoma/*chemistry/mortality/pathology | 3 | 37.0 |
*Models, Molecular | 2 | 1.0 |
Immunohistochemistry/*methods | 3 | 3.0 |
Lung/pathology | 2 | 2.0 |
Placenta/*chemistry | 2 | 5.0 |
Proto-Oncogenes | 8 | 4.0 |
Recombinant Fusion Proteins/chemistry | 2 | 2.0 |
Trans-Activation (Genetics)/drug effects | 3 | 1.0 |
Skin/cytology | 2 | 1.0 |
Antigens, CD/analysis | 2 | 0.0 |
Antigens, CD57 | 3 | 4.0 |
Membrane Glycoproteins/analysis | 3 | 1.0 |
Chromosome Disorders | 2 | 0.0 |
Immunization | 2 | 0.0 |
Ovary/*chemistry | 3 | 17.0 |
Lung Neoplasms/*metabolism/mortality/pathology | 2 | 12.0 |
Ovary/metabolism | 2 | 2.0 |
*Proto-Oncogenes | 17 | 2.0 |
Receptors, Estrogen/analysis/*biosynthesis | 2 | 40.0 |
DNA | 3 | 0.0 |
Neoplasms/*chemistry | 2 | 14.0 |
Proto-Oncogene Protein c-met | 4 | 3.0 |
Stomach Neoplasms/*metabolism | 2 | 4.0 |
Oncogene Proteins v-erbB | 4 | 44.0 |
Isoantigens/analysis | 2 | 12.0 |
Chromosomes, Human, Pair 17/*ultrastructure | 2 | 9.0 |
Transforming Growth Factor alpha/analysis/*physiology | 2 | 66.0 |
Intestinal Mucosa/cytology | 2 | 15.0 |
Carcinoma, Non-Small-Cell Lung/drug therapy | 3 | 60.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 3 | 3.0 |
Agar/chemistry | 2 | 33.0 |
Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors | 4 | 40.0 |
Carcinoma, Squamous Cell/*metabolism/pathology/*radiotherapy | 2 | 66.0 |
Adaptor Proteins, Vesicular Transport/metabolism | 3 | 20.0 |
Tumor Cells, Cultured/*drug effects/pathology | 2 | 12.0 |
Breast/metabolism | 2 | 2.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
RNA, Messenger/isolation & purification/metabolism | 2 | 10.0 |
RNA, Neoplasm/isolation & purification/metabolism | 2 | 20.0 |
Prevalence | 3 | 0.0 |
Random Allocation | 3 | 0.0 |
Anticarcinogenic Agents/*therapeutic use | 2 | 10.0 |
Receptor, erbB-2/analysis/biosynthesis | 2 | 66.0 |
Recombinant Fusion Proteins/therapeutic use | 2 | 8.0 |
Oligonucleotides, Antisense/chemistry/*pharmacology | 2 | 40.0 |
Second Messenger Systems | 2 | 2.0 |
Brain Neoplasms/*genetics/metabolism/pathology | 3 | 13.0 |
Tumor Virus Infections | 2 | 13.0 |
Antibodies, Bispecific/*immunology/therapeutic use | 2 | 50.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Neoplasms/immunology/*therapy | 2 | 3.0 |
Breast Neoplasms/*blood supply/mortality/*pathology/surgery | 2 | 66.0 |
Head and Neck Neoplasms/*chemistry | 4 | 44.0 |
Receptor, Epidermal Growth Factor/*analysis/metabolism/physiology | 2 | 100.0 |
Proto-Oncogenes/genetics | 3 | 9.0 |
Epidermal Growth Factor/genetics/physiology | 2 | 66.0 |
*Genes, Structural, Neoplasm | 2 | 33.0 |
Tissue Preservation | 3 | 10.0 |
Dinoprostone/*pharmacology | 3 | 5.0 |
Cadherins/*metabolism | 3 | 4.0 |
Protein Array Analysis/*methods | 2 | 20.0 |
Carcinoma, Squamous Cell/diagnosis/genetics/metabolism | 2 | 66.0 |
Carcinoma, Transitional Cell/genetics/*pathology | 2 | 50.0 |
DNA, Neoplasm/genetics/isolation & purification | 3 | 2.0 |
Receptors, Progesterone/*genetics | 2 | 9.0 |
RNA, Messenger/*analysis/genetics | 2 | 4.0 |
Progesterone/pharmacology | 2 | 1.0 |
Xenopus laevis | 2 | 0.0 |
Adenocarcinoma/chemistry | 2 | 14.0 |
Bladder Neoplasms/chemistry/*therapy | 2 | 100.0 |
Pseudomonas aeruginosa | 2 | 11.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Transforming Growth Factors/*analysis/genetics | 3 | 100.0 |
RNA/analysis/genetics | 2 | 9.0 |
Oncogene Protein p21(ras)/metabolism | 2 | 16.0 |
Pancreas/chemistry | 2 | 8.0 |
Adenoma/chemistry | 2 | 15.0 |
Goiter/metabolism | 2 | 20.0 |
Thyroid Neoplasms/*chemistry | 2 | 18.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Cyclin B/metabolism | 2 | 2.0 |
Cysteine Endopeptidases | 2 | 4.0 |
Signal Transduction/*drug effects/genetics | 3 | 30.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
Pancreatic Neoplasms/genetics | 2 | 5.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 2 | 4.0 |
Carcinoma/*metabolism/mortality | 2 | 40.0 |
Biotin | 2 | 3.0 |
Platelet-Derived Growth Factor/genetics | 4 | 12.0 |
Receptors, Platelet-Derived Growth Factor/genetics | 2 | 13.0 |
Transforming Growth Factor beta/genetics | 2 | 2.0 |
ABO Blood-Group System/*immunology | 2 | 16.0 |
Carcinoma/*chemistry/pathology | 2 | 12.0 |
Neoplasm Proteins/genetics/metabolism | 3 | 2.0 |
Estrogens/pharmacology | 2 | 2.0 |
Head and Neck Neoplasms/drug therapy | 2 | 50.0 |
Arsenites/*pharmacology | 2 | 11.0 |
Quinazolines/chemical synthesis/*chemistry/pharmacology | 2 | 100.0 |
Catechin/*analogs & derivatives/*pharmacology | 3 | 13.0 |
Cyclin E/metabolism | 2 | 1.0 |
Cyclins/biosynthesis | 2 | 2.0 |
Ribosomal Protein S6 Kinases, 90-kDa/metabolism | 2 | 18.0 |
Tumor Suppressor Proteins/biosynthesis | 3 | 18.0 |
Genes, Neurofibromatosis 1 | 2 | 6.0 |
Aging/*metabolism | 2 | 0.0 |
Poly A/genetics/isolation & purification | 2 | 5.0 |
RNA/genetics/isolation & purification | 3 | 2.0 |
RNA, Neoplasm/genetics/isolation & purification | 3 | 4.0 |
Receptor, Epidermal Growth Factor/drug effects/immunology/*metabolism | 2 | 66.0 |
Tumor Cells, Cultured/metabolism/pathology | 2 | 4.0 |
Glioblastoma/metabolism | 2 | 8.0 |
1-Phosphatidylinositol 3-Kinase/*antagonists & inhibitors | 2 | 10.0 |
Radioligand Assay/methods | 3 | 17.0 |
Carcinoma, Squamous Cell/chemistry/*genetics | 2 | 50.0 |
Mouth Neoplasms/chemistry/*genetics | 2 | 66.0 |
Receptors, Cell Surface/*genetics/metabolism | 2 | 2.0 |
Receptors, Platelet-Derived Growth Factor | 3 | 9.0 |
Multigene Family/*genetics | 2 | 1.0 |
Breast Neoplasms/drug therapy/*metabolism | 3 | 13.0 |
Conjunctiva/*metabolism | 2 | 14.0 |
Pterygium/metabolism | 2 | 100.0 |
Endpoint Determination | 2 | 12.0 |
Quinazolines/*adverse effects/pharmacology/therapeutic use | 2 | 100.0 |
Breast Neoplasms/genetics/metabolism | 2 | 4.0 |
Telomerase/genetics | 2 | 12.0 |
Receptor, Insulin/*metabolism | 2 | 3.0 |
Receptors, Fibroblast Growth Factor/genetics/*metabolism | 2 | 5.0 |
Pancreas/metabolism | 2 | 2.0 |
Pancreatitis/metabolism | 2 | 25.0 |
RNA, Neoplasm/*analysis | 3 | 6.0 |
Menopause/physiology | 2 | 13.0 |
Glioma/genetics | 2 | 9.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Mice, Inbred Strains | 3 | 0.0 |
Vascular Endothelial Growth Factor A/metabolism | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 2 | 4.0 |
Cell Cycle Proteins/*metabolism | 2 | 0.0 |
Ions | 2 | 2.0 |
Cytosol/chemistry | 2 | 3.0 |
Breast/pathology | 3 | 10.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/*analysis/genetics | 2 | 6.0 |
Receptors, Transferrin/analysis | 2 | 5.0 |
Cell Division/drug effects/*physiology | 2 | 7.0 |
Carboplatin/administration & dosage | 2 | 4.0 |
Paclitaxel/administration & dosage | 2 | 7.0 |
Receptors, Cell Surface/genetics/metabolism | 2 | 3.0 |
Brain Neoplasms/*genetics/pathology/therapy | 2 | 66.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
Adenocarcinoma/*genetics/metabolism/pathology | 2 | 6.0 |
Epidermal Growth Factor/antagonists & inhibitors/metabolism | 3 | 75.0 |
Receptors, Transferrin/*analysis | 3 | 27.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology/therapeutic use | 3 | 10.0 |
*Antigens, CD | 2 | 0.0 |
Gelatinase B/*biosynthesis/genetics | 2 | 28.0 |
Antibodies, Monoclonal/diagnostic use/immunology | 3 | 11.0 |
Brain Neoplasms/*chemistry | 2 | 33.0 |
Histocytochemistry | 3 | 0.0 |
Singapore/epidemiology | 2 | 6.0 |
Transforming Growth Factor alpha/immunology | 2 | 40.0 |
DNA Topoisomerases, Type II, Eukaryotic/metabolism | 2 | 33.0 |
Proto-Oncogene Protein c-kit/genetics/*metabolism | 2 | 18.0 |
Head and Neck Neoplasms/*metabolism/pathology | 2 | 9.0 |
Cell Membrane/analysis | 2 | 6.0 |
Breast Neoplasms/*analysis/pathology | 9 | 45.0 |
Carcinoma, Squamous Cell/analysis | 3 | 33.0 |
Cell Nucleus/analysis | 3 | 14.0 |
Cytosol/analysis | 2 | 6.0 |
Carcinoma, Intraductal, Noninfiltrating/*analysis/pathology | 2 | 100.0 |
Adenocarcinoma/analysis | 2 | 15.0 |
Breast Neoplasms/*analysis | 5 | 12.0 |
Colorectal Neoplasms/*drug therapy/*pathology | 2 | 50.0 |
Transforming Growth Factors/biosynthesis/*genetics | 2 | 66.0 |
Tamoxifen/therapeutic use | 2 | 3.0 |
Colorectal Neoplasms/genetics/*metabolism | 2 | 9.0 |
*Genes, Structural | 5 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols | 2 | 6.0 |
Tumor Cells, Cultured/analysis | 2 | 13.0 |
Soft Tissue Neoplasms/*metabolism/pathology/therapy | 2 | 66.0 |
Immunologic Techniques | 2 | 0.0 |
Stomach Neoplasms/*analysis/pathology | 2 | 33.0 |
Receptor, Epidermal Growth Factor/analysis/genetics/*metabolism | 3 | 50.0 |
Receptor, erbB-2/analysis/genetics/*metabolism | 2 | 100.0 |
Adenocarcinoma/genetics/metabolism | 2 | 10.0 |
Arthritis, Rheumatoid/*complications/radiography | 2 | 10.0 |
Atlanto-Axial Joint/radiography | 2 | 10.0 |
*Cervical Vertebrae/radiography | 2 | 9.0 |
Dislocations/etiology/radiography | 2 | 10.0 |
Neck Pain/etiology | 2 | 10.0 |
Spinal Diseases/*etiology/radiography | 2 | 10.0 |
*Child Development | 2 | 6.0 |
Electroencephalography | 3 | 1.0 |
Motor Cortex/*anatomy & histology/*growth & development | 2 | 15.0 |
Seizures/surgery | 2 | 15.0 |
Skull/*anatomy & histology/*growth & development | 2 | 15.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Neuregulin-1/metabolism | 2 | 15.0 |
Chlorides/*metabolism | 2 | 2.0 |
Cholinergic Agonists/pharmacology | 2 | 8.0 |
Risk | 3 | 0.0 |
Mouth Neoplasms/*metabolism/pathology | 2 | 16.0 |
Computer Simulation | 4 | 1.0 |
Receptor, erbB-2/chemistry/*metabolism | 2 | 22.0 |
Carcinoma, Squamous Cell/*analysis | 2 | 28.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Carcinoma, Squamous Cell/enzymology/*pathology | 2 | 40.0 |
Head and Neck Neoplasms/enzymology/*pathology | 2 | 66.0 |
Receptor Cross-Talk/*physiology | 2 | 15.0 |
Down-Regulation/drug effects/physiology | 2 | 5.0 |
Dipeptides/pharmacology | 3 | 7.0 |
Epithelial Cells/drug effects/metabolism | 3 | 3.0 |
Epidermal Growth Factor/*chemistry/metabolism | 2 | 12.0 |
Protein Kinase C/*metabolism | 4 | 1.0 |
Head and Neck Neoplasms/*drug therapy/pathology | 3 | 50.0 |
Receptor, Epidermal Growth Factor/*drug effects/genetics | 3 | 75.0 |
Pertussis Toxin/pharmacology | 2 | 3.0 |
Taiwan/epidemiology | 2 | 1.0 |
Pyrroles/pharmacology | 2 | 4.0 |
Ki-67 Antigen/biosynthesis | 2 | 2.0 |
Receptor, erbB-2/*drug effects | 2 | 50.0 |
Subtraction Technique | 2 | 5.0 |
Receptor, erbB-2/analysis/*metabolism | 2 | 66.0 |
Colorectal Neoplasms/*blood/pathology | 2 | 25.0 |
Deoxycytidine/*analogs & derivatives/pharmacology | 2 | 8.0 |
Urinary Plasminogen Activator/analysis | 3 | 18.0 |
*Flavonoids | 2 | 8.0 |
Recombinant Proteins/chemistry/pharmacology | 2 | 8.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Proteomics/*methods | 2 | 9.0 |
GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 5.0 |
*Chromosomes, Human, 6-12 and X | 2 | 1.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/*biosynthesis | 2 | 3.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/*genetics | 2 | 100.0 |
Antibodies/metabolism | 2 | 2.0 |
Hydrazines/pharmacology | 2 | 13.0 |
Recombinant Fusion Proteins/genetics/*metabolism | 2 | 14.0 |
Prostatic Neoplasms/*drug therapy/genetics | 2 | 100.0 |
Protein Kinase C/antagonists & inhibitors | 2 | 1.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Membrane Proteins/biosynthesis/genetics | 2 | 5.0 |
Disulfides/chemistry | 2 | 2.0 |
Vacuolar Proton-Translocating ATPases/*antagonists & inhibitors | 2 | 66.0 |
Gelatinase B/metabolism | 2 | 3.0 |
Heterotrimeric GTP-Binding Proteins/metabolism | 2 | 5.0 |
Blood Specimen Collection/*methods | 3 | 13.0 |
*Catheterization, Central Venous | 3 | 30.0 |
Neoplasms/nursing | 3 | 33.0 |
Endothelial Growth Factors/genetics/metabolism | 2 | 4.0 |
Intercellular Signaling Peptides and Proteins/genetics/metabolism | 2 | 9.0 |
Lymphokines/genetics/metabolism | 2 | 5.0 |
